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Welanders distala myopati (WDM) orsakas av mutationen p.E384K i genen TIA1. Mutationen antas vara sjukdomsalstrande på 
grund av en ökad produktion av protein, som relaterats till formationen av stressgranuler (Hackman et al. 2013). Även 
omgivningsfaktorer har föreslagits verka i sjukdomens utveckling: en ökad mängd stressgranuler har observerats i celler som 
behandlats med köldshock jämfört med celler som förvarats i 37°C (Hofmann et al. 2012). 
 
I patienter med WDM-liknande symptom som undersökts för förändringar i TIA1 har en p.N357S-förändring noterats förrikad. 
Denna förändring har tidigare anmälts som en polymorfism. Förändringen i fråga ligger i samma prionliknande domän i exon 5 som 
WDM-orsakande förändringen p.E384K. Därmed kunde p.N357S-förändringen öka predispositionen till aggregering. 
 
Pro gradu –arbetet är uppdelat i två delar: 
• p.N357S-polymorfismens effekt på stressgranulsbildningen i arsenitbehandle celler 
• Köldshockens effekt på stressgranulsbildningen  
 
Resultaten påvisar, att förändringen p.N357S i TIA1 orsakar en förändring i det translaterade proteinets beteende. I likhet med 
p.E384K-förändringen orsakar även p.N357S en ökad mängd stressgranuler i arsenitbehandlade celler. Däremot tyder resultaten 
på att stressgranulerna återbildas snabbare i fluorescence recovery after photobleaching-studier (FRAP) I p.N357S-transfekterade 
celler än i celler som transfekterats med TIA1 p.E384K och vildtyp. 
 
Köldshocksexperimenten tyder på att det finns en viss skillnad mellan bildningen av stressgranuler i celler transfekterade med 
p.E384K och vildtyps-TIA1. Detta stöder tidigare publicerade resultat om p.E384K-förändringens påverkan på stressresponsen och 
stressgranulsbildningen, och även köldshock som stressinducerande behandling. 
 
Använda metoder: PCR, transformation, DNA-ekstraktion, cellkultur, transfektion, induktion av stressgranulsformation med 
arsenitbehandling och köldshock. Cellerna kultiveras på brunnsplattor, fotograferas och datat analyseras med en automatiserad 
High Content biildanalysmetod (CellInsight-platform). p.N357S-celler analyserades även med FRAP. 
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Tiivistelmä – Referat – Abstract 
 
Welander Distal Myopathy (WDM) is caused by the p.E384K mutation in the TIA1 gene. The mutation supposedly causes the 
disease by a gain-of-function mechanism related to the formation of stress granules (Hackman et al. 2013). Also environmental 
factors have been proposed to affect the development of the disease: an increased number of stress granules has been observed 
in cells treated with cold shock compared to cells kept in 37 °C (Hofmann et al. 2012). 
 
When patients with WDM-like symptoms have been screened for changes in TIA1, an p.N357S-change has been found enriched 
in these patients. The p.N357S-change has earlier been reported as a polymorphism. The change in question is located in the 
same prion-like domain in exon 5, in which the p.E384K-mutation also lies. Therefore, the p.N357S-change could affect the 
predisposition to aggregation. 
 
The pro gradu project is divided into two parts: 
• The effect of the p.N357S polymorphism on stress granule formation in arsenite and possibly other stress treated cells 
• The effect of cold shock on stress granule formation on wild type and p.E384K TIA1 
 
The results indicate, that the p.N357S change in TIA1 causes a change in the translated protein’s behavior. Similarly to the 
p.E384K change, the p.N357S change also induces an increased amount of stress granules in arsenite treated cells. However, the 
results also show that the stress granules recover faster in fluorescence recovery after photobleaching (FRAP) studies p.N357S 
transfected cells as compared to TIA1 p.E384K and wild type transfected cells. 
 
The cold shock experiment indicates that there is a difference in the stress granule formation between cells transfected with 
p.E384K and wild type TIA1. This supports previously published results of the effect of the p.E384K change on the stress response 
and stress granule formation, and also the use of cold shock as a stress inducing treatment. 
 
Used methods: PCR, transformation, DNA-extraction, cell culture, transfection, induction of stress granule formation by arsenite 
treatment and cold shock. The cells are cultivated on well plates, imaged and the data is analyzed with an automatized high 
content image analysis method (the CellInsight-platform). p.N357S cells were also analyzed with FRAP. 
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PKR  protein kinase R protein 
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RRM  RNA recognition motif 
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TIA1  TIA1 cytotoxic granule-associated RNA-binding protein gene 
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1. INTRODUCTION	  
 
Welander Distal Myopathy (WDM) is a dominantly inherited late-onset distal muscular dystrophy, 
which can also occur sporadically (Welander 1951). The disease has been encountered only in 
Finland, Sweden and one family in Great Britain (Hackman et al. 2013). The causative mutation 
was pinpointed in 2013 to a single nucleotide polymorphism (SNP) in the gene TIA1 cytotoxic 
granule-associated RNA-binding protein (TIA1), causing changes in the behavior of the gene 
product (TIA1) in stress conditions (Hackman et al. 2013).  
 
TIA1 shuttles between the nucleus and cytoplasmic protein-RNA aggregates called stress granules 
(SG). SGs form as a result of the cells stress response (Anderson and Kedersha, 2008, and are 
measurable in both size and number when a fluorescent tag, such as GFP, is added to the TIA1 
protein. Changing cell culture conditions can induce the stress response, and thus the formation of 
SGs. 
 
The thesis is divided into two parts: 
 
• Subproject I is aimed at researching the behavior of a SNP (p.N357S) enriched in patients with 
symptoms similar to those of patients with WDM by transfecting HeLa cells (derived from 
human cervical cancer) with TIA1 wild type and p.N357S. Subsequently, a stress response is 
induced by treating the cells with sodium arsenite, and the change in SG formation is studied. 
 
• Subproject II, is aimed at researching the effect of cold shock in HeLa cells transfected with 
TIA1 wild type and TIA1 harboring the WDM-causing mutation p.E384K. The cold shock has 
been proven to induce a stress response (Hoffmann et al. 2012) and the aim is to study whether 
the WDM-causing mutation also changes the stress response in cold shock treated cells. 
 
This thesis work was conducted at the Folkhälsan Institute of Genetics in the research group of 
neuromuscular diseases led by Professor Bjarne Udd. The supervisors of the work were Docent 
Peter Hackman, PhD Per Harald Jonson and FD Jaakko Sarparanta from the Udd group at the 
Folkhälsan Institute of Genetics. Imaging studies were done at the Biomedicum Imaging Unit and 
the Institute of Biotechnology Light Microscopy Unit at the University of Helsinki. Sequencing was 
performed by the Institute for Molecular Medicine Finland (FIMM). The work was funded by 
Samfundet Folkhälsan i svenska Finland rf and Jane and Aatos Erkko foundation. 
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2. SKELETAL	  MUSCLE	  
 
There are three types of muscle tissue in the human body: skeletal, cardiac and smooth muscles. 
Skeletal muscles are used for voluntary controlled movement under the somatic nervous system, 
whilst cardiac and smooth muscle tissues are used for involuntary movements, such as the 
contraction of the heart and peristaltic movements in the gastrointestinal tract (Alberts et al. 1994). 
Of these types of muscle tissue, the skeletal and cardiac muscle tissue are considered striated due to 
their organized composition (Craig and Padron, 2004). 
 
The average human body consists of about 40% in mass of striated, skeletal muscle (Marieb and 
Hoehn 2010). As its name indicates, skeletal muscle is connected to the skeleton (usually by 
tendons) as to allow contractions in the tissue to create movement in parts of the body in reference 
to the body itself (MacIntosh et al. 2006). The number of muscle cells in adult mammals is fixed. 
Muscle mass can therefore be built only by enlarging existing muscle cells, instead of increasing 
their number (Campbell et al. 2008). 
 
Skeletal muscle tissue can be divided into two major groups, the slow, oxidative type I and the fast, 
glycolytic type II muscle fibers. The human skeletal muscles are composed of a mixture of these 
two types (Silverthorn 2010). The type I is mainly found in large muscles meant for aerobic and 
long term activity and therefore contain many mitochondria and much myoglobin. The type II fibers 
are further divided into three different groups according to the neuron that innervates the motor 
unit: 
i) Type IIA: produces energy either aerobically or anaerobically 
ii) Type IIB: produces energy anaerobically, can produce powerful yet short contractions 
iii) Type IIX: produces energy by lactic acid fermentation, produces fast contractions but not for 
long periods of time (Stone and Stone 2006). 
 
Striated, skeletal muscle consists of organised bundles of muscle fibers (Fig. 1). These fibers are 
large single cells (Ø = 10‒100 µm) with multiple nuclei that form by fusion of smaller muscle cells. 
In healthy muscle cells, the nuclei are located on the edges of the cell, beneath the plasma 
membrane, to make room in the cytoplasm for the contractile element of the muscle, called the 
myofibrils (Ø = 1‒2 µm). The cylindrical myofibrils span typically from one end of the cell to the 
other. Several contractile units of about 2.2 µm in length, called sarcomeres, build up each 
myofibril (Silverthorn 2010). 
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Figure	  1.	  The	  structure	  of	  a	  striated	  muscle	  fiber.	  (Reprinted	  with	  permission	  from	  Jaakko	  Sarparanta)	  
 
 
Sarcomeres contain actin and myosin filaments that alternately overlap each other and give the 
muscle its striated look of alternating light and dark bands, visible in a light microscope (Craig and 
Offer 2004). The bands are separated by Z-discs, located in the middle of the light bands, and M-
lines, located in the middle of the dark bands. The actin and myosin filaments are connected to the 
Z-discs and M-lines respectively (Alberts et al. 2002). The structure of the sarcomere is shown in 
Fig. 2. 
 
 
 
Figure	  2.	  The	  structure	  of	  the	  sarcomere.	  Myosin	  shown	  in	  green,	  actin	  filaments	  in	  blue.	  (Reprinted	  with	  permission	  
from	  Jaakko	  Sarparanta)	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3. MUSCULAR	  DYSTROPHIES	  
 
Muscular dystrophies are a widely varying group of inherited myogenic disorders. The main trait of 
these disorders is a progressively weakening musculoskeletal system and the reduced mobility that 
follows. Generally the weakness is presented in a limb-girdle pattern, but some myopathies cause 
distal weakness, which may easily be mistaken for a neurogenic feature (Illa 2000). 
 
Several different types of muscular dystrophies have been identified as separate disorder groups 
based on clinical investigations, such as the results of muscle biopsies, creatine phosphokinase (CK) 
levels in blood, electromyography, electrocardiography and lately by DNA analysis. Among the 
identified disorders and disorder groups are Duchenne, Becker, limb-girdle, congenital, 
fascioscapulohumeral, myotonic, oculopharyngeal, distal and Emery-Dreifuss muscular dystrophy. 
These disorders can be further grouped by the muscle groups affected into six major forms (Fig. 3). 
Nonetheless, the ages of onset, speed of progression and severity of the diseases vary even inside 
each group (Illa 2000).  
 
As of yet, there are few pharmacological treatments for the disorders, and no way of affecting the 
long-term course of the diseases to an eminent degree has been found. Recent advances in gene 
manipulation and stem-cell therapy may provide treatment to patients in the future, but cautious 
optimism is advised (Emery 2002). 
 
 
Figure	   3.  Depiction	   of	   affected	  muscles	   in	   different	   muscular	   dystrophies.	   A.	   Duchenne-­‐type	   and	   Becker-­‐type;	   B.	  
Emery-­‐Dreifuss;	   C.	   limb-­‐girdle;	   D.	   Fascioscapulohumeral;	   E.	   Distal;	   F.	   Oculopharyngeal.	   Affected	   areas	   are	   shaded.	  
Adapted	  from	  Emery,	  2002. 
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4. DISTAL	  MYOPATHIES	  
 
Distal myopathies are a heterogeneous group of muscular dystrophies, which are inherited or 
occurring as sporadic muscular diseases. The common feature is muscular weakness and atrophy 
that progresses from the distal muscles of the extremities towards the proximal muscles closer to the 
body (Griggs et al. 1994). 
 
The first distal myopathy was thoroughly described in 1951 by Lisa Welander, and she was also the 
first to establish the existence of distal myopathies, as opposed to the limb-girdle pattern of 
proximal dystrophies (Welander 1951). Her publication is considered the landmark publication for 
distal myopathies, although the very first case description of a distal muscular dystrophy is often 
attributed to Gowers in 1902 (Gowers 1902, Mastaglia 1999). The first distal muscular dystrophy 
gene, dysferlin (DYSF), was identified in 1998 (Illa 2000). 
 
 
4.1 CLINICAL	  ASPECTS	  
 
Distal myopathies are diagnosed using several different methods to assess the condition of the 
patient’s affected skeletal muscle tissue and motor neurons. This is done by a series of tests such as, 
electromyography (EMG), blood tests, magnetic resonance imaging (MRI) and biopsy examination. 
Reviewing patient family disease history also contributes to the diagnostic process (Borg et al. 
1991). 
 
Since distal myopathies are normally caused by an inherited genetic feature, patient family history 
is taken into account in detail. Some distal myopathies are however caused by a sporadic change, 
thus the possibility of a distal myopathy cannot be excluded solely based on the lack of disease 
occurrence in the patients family. 
  
EMG is a diagnostic method, which is used to measure the electrical activity in the skeletal muscles. 
The aim of the technique is to assess whether the muscle weakness is caused by changes in muscle 
tissue (myopathy) or the nerves controlling it (neuropathy) (Logigian et al. 2010). 
 
Blood tests include creatine kinase (CK) level analysis as default in patients with a suspected 
myopathic condition. Elevated CK levels are often, but not always, seen in patients with muscle 
disorders. CK is an enzyme functioning as an energy reservoir in tissues that are highly dependent 
on adenosine triphosphate (ATP) as their source of energy. Skeletal muscle is a prime example, but 
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several different tissues fall into this category – among them, the brain and the photoreceptor cells 
of the retina. High levels of CK in the blood indicates damage to such tissues, but is alone not a 
basis for diagnosis of a myopathy, since it could be caused by damage to other ATP-dependent 
tissues. In addition, not all myopathies lead to an elevated CK level in the patient (Hilton-Jones et 
al. 2010). 
 
MRI is used to assess anatomical and physiological aspects of a patient using strong magnetic 
fields. Different distal myopathies cause distinct muscle weakness patterns, which can be identified 
with MRI of the muscles (Logigian et al. 2010). 
 
In terms of histological changes, distal myopathies show a large variation of changes in the affected 
muscles. Muscle fiber necrosis (dead muscle fibers), split muscle fibers, internal nuclei, inclusion 
bodies and rimmed vacuoles (multilaminated vacuole-like constructs) are some of the most 
characteristic features indicating muscle damage (Illa 2000). 
 
Patients with distal myopathies show myopathic changes in electromyography (EMG) studies and 
often have an elevated creatine kinase (CK) level in blood tests. Histological changes in muscle 
biopsies vary to a large degree, and are mainly nonspecific. No change has been observed in nerve 
conduction studies in distal myopathy patients – neural involvement is a feature of neuropathies or 
some other neuromuscular diseases (Illa 2000). 
 
 
4.2 CLASSIFICATION	  
 
Only a few distal myopathies had been described and identified before the new era of molecular 
genetics. Now, at least 20 different distal myopathies have been separated into distinct disorders. In 
some of these cases, the underlying genetic changes are still unknown (Udd 2012). 
 
Being a widely varying group of disorders, there are several ways in which to classify distal 
myopathies. In Fig. 4 and Table 1 a traditional classification for the six major distal myopathy 
types (Tibial muscular dystrophy, Myofibrillar myopathy 4, Welander distal myopathy, Laing 
myopathy, Nonaka myopathy and Miyoshi muscular dystrophy) is shown. This sort of classification 
takes into account the mode of inheritance, the muscle groups affected and the age of onset, which 
are traditional clinical forms of investigation. 
 
 15 
 
Figure	  4.	  Traditional	  classification	  of	  the	  six	  major	  distal	  myopathy	  types.	  Adapted	  from	  Mastaglia,	  1999	  and	  Udd	  
2012.	  
 
 
 
 
 
Table	  1.	  The	  major	  six	   forms	  of	  distal	  myopathies	  classified	  according	  to	  distinguishing	  features	  by	  their	  established	  
scientific	  names.	  Adapted	  from	  Mastaglia	  1999.	  
 WDM	   TMD	   MFM4	   MPD1	   NM	   MMD1	  
OMIM	  #	   604454 600334 609452 160500 605820 254130 
Inheritance	   AD AD AD AD AR/sporadic AR/sporadic 
Gene	  	   TIA1 TTN LDB3 MYH7 GNE DYSF 
Age	  of	  onset	   >40 >35 25-50 4-25 20-30 15-30 
Site	  of	  onset	   Hands Legs Legs Legs Legs Legs 
Leg	  compartment	   Anterior Anterior Anterior Anterior Both Posterior 
Proximal	  weakness	   - + (late) + (late) + + (late) + (late) 
Neck	  weakness	   - - - + + + (late) 
CK	   N or mild ↑ N or mild ↑ 2-5X <3X <5X 10-100X 
Myopathic	   + + + + + + 
Spontaneous	  activity	   + + + + + + 
RV’s	  and	  TFI	   + + ? - + - 
Fiber	  necrosis	   - + + + - + 
AD	  =	  autosomal	  dominant,	  AR	  =	  autosomal	  recessive,	  MFM4	  =	  Myofibrillar	  Myopathy	  4/ZASPopathy,	  MMD1	  =	  Miyoshi	  
muscular	   dystrophy,	  MPD1	   =	  Myopathy	   Distal	   1	   (Laing	  myopathy),	   N	   =	   normal,	   NM	   =	  Nonaka	  Myopathy,	   OMIM	   =	  
Online	   Mendelian	   Inheritance	   in	   Man,	   RVs	   =	   Rimmed	   vacuoles,	   TFIs	   =	   tubulofilamentous	   inclusions,	   TMD	   =	   Tibial	  
Muscular	  Dystrophy	  WDM	  =	  Welander	  Distal	  Myopathy.	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The methods of molecular biology have advanced rapidly during the last years. With the increased 
understanding of the genetic backgrounds and molecular pathomechanisms of distal myopathies, it 
has been suggested that the disorders should be categorized not necessarily by phenotype, but rather 
by the disease causing gene mutations. The traditional classification is restricted to only mode of 
inheritance, age of onset and the first muscle groups affected. Clinical symptoms, such as those 
above, give clues as to which category the patient may fall, but as both genetic factors and 
phenotypic traits can vary widely throughout patients, these principles start to be out-dated 
(Malicdan and Nonaka 2008).  
 
Since there is an overlap in phenotypes and a large increase of identified disorders, a classification 
based on the genetic background of the disease could be of use (Udd 2012). A guideline for 
pinpointing the underlying genetic variations that cause certain clinical features is given in Fig. 5.  
 
 
 
Figure	  5.	  A	  general	   guideline	   to	  determine	  possible	   loci	   for	  genetic	   variation	  classed	  by	   clinical	   features.	  Genes	  are	  
displayed	  in	  italics.	  AD	  =	  autosomal	  dominant,	  Ant	  =	  anterior	  onset,	  AR	  =	  autosomal	  recessive,	  Post	  =	  posterior	  onset,	  
Adapted	  from	  Udd,	  2012.	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As inherited disorders, all distal myopathies are caused by genetic mutations in the DNA. Often, 
these proteins are expressed in the sarcomeres, the sarcoplasm, the cytoskeleton and the cytoplasm 
(Malicdan and Nonaka, 2008). 
 
A more recent summary of distal myopathies and the genes and proteins related to them are shown 
in Table 2. 
 
 
Table	  2.	  Genetically	  determined	  distal	  myopathies.	  Adapted	  from	  Udd,	  2012.	  
 Gene/Protein	   OMIM	   Reference	  
1.	  Late	  adult	  onset	  autosomal	  dominant	  forms	   	   	   	  
a. Welander distal myopathy TIA1/TIA1 #604454 Welander 1951, Hackman 2013 
b. Tibial muscular dystrophy (TMD, UDD myopathy) TTN/Titin #600334 Udd et al. 1993 
c. Distal myotilinopathy MYOT/Myotilin #609200 Pénisson-Besnier et al. 2006 
d. ZASPopathy (Markesbery-Griggs) LDB3/ZASP #605906 Griggs et al. 2007 
e. Matrin3 distal myopathy (VCPDM, MPD2) MATR3/Matrin3 #606070 Senderek et al. 2009 
f. VCP-mutated distal myopathy VCP/VCP N/A Palmio et al. 2011 
g. Alpha-B crystalline mutated distal myopathy CRYAB/ αB-crystallin N/A Reichlich et al. 2010 
2.	  Adult	  onset	  autosomal	  dominant	  forms	   	     
a. Desminopathy DES/Desmin #601419 Sjöberg et al. 1999 
b. Distal ABD-filaminopathy FLNC/Filamin-C #614065 Duff et al. 2011 
c. Finnish-MPD3 Unknown %610099 Mahjneh et al. 2003 
d. Italian 19p13-linked distal myopathy Unknown %601846 Servidei et al. 1999 
e. US-Polish family Unknown N/A Felice et al. 1999 
f. Oculopharyngeal distal myopathy OPDM Unknown %164310 Durmus et al. 2011 
3.	  Early	  onset	  autosomal	  dominant	  forms	      
a. Laing distal myopathy (MPD1) MYH7/Beta-MyHHC #160500 Laing et al. 1995 
b. KLHL9 mutated distal myopathy KLHL9/KLHL9 N/A Cirak et al. 2010 
4.	  Early	  onset	  autosomal	  recessive	  forms	      
a. Distal nebulin myopathy NEB/Nebulin #256030 Wallgren-Petterson et al. 2007 
5.	  Early	  adult	  onset	  autosomal	  recessive	  forms	      
a. Miyoshi myopathy (MM) DYSF/Dysferlin #254130 Miyoshi et al. 1986 
b. Distal Anoctaminopathy ANO5/Anoctamin-5 #613319 Bolduc et al. 2010 
c. Distal myopathy with rimmed vacuoles (Nonaka) GNE/GNE #605820 Noanka et al. 1981 
d. Oculopharyngeal distal myopathy, OPDM Unknown %134310 Durmus et al. 2011 
6.	  Adult	  onset	  autosomal	  recessive	  form	      
a. Calf myopathy non-DYSF/ANO5 Unknown %613318 Linssen et al. 1998 
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5. WELANDER	  DISTAL	  MYOPATHY	  
 
Welander Distal Myopathy (WDM, MIM #604454) is an autosomal, dominantly inherited late onset 
muscular dystrophy prevalent in Sweden and certain parts of Finland. Patients experience the first 
symptoms at around 50 years of age (40–60 y). The disease causes progressive muscular weakness 
in the distal muscles (Welander, 1951).  
 
In 1951 Lisa Welander published a report, which knocked down earlier skepticism around the 
existence of a myopathy that would predominantly affect distal muscles in the body, as opposed to 
myopathies that cause weakness in proximal muscles. She studied 249 affected individuals from 72 
separate pedigrees, mainly from central parts of Sweden (Welander 1951). A Swedish group 
mapped WDM to chromosome 2p13 in 1999 (Åhlberg et al. 1999).  In 2013 a mutation in the 
RNA-binding protein TIA1 was identified to be the WDM causing factor (Hackman et al. 2013). 
 
5.1. CLINICAL	  IMAGE	  
WDM is a late onset disease, with the first symptoms of muscular weakness setting in at between 
40 and 60 years of age, affecting men and women equally. Patients experience weakness primarily 
in the small muscles and extensors of hands and fingers, which leads to the loss of fine motor skills. 
At later stages of the disease, extensor muscles in the lower limbs might also develop symptoms, 
most often in toe and ankle extensors. Even in later stages of the disease, symptoms in flexor or 
proximal muscles are rarely developed. Cardiomyopathy, dysphagia and respiratory failure are 
never observed (Welander 1951, Borg et al. 1998). Except for loss of ankle reflexes in later stages 
of the disease, tendon reflexes are mainly preserved throughout the disease (Udd, 2014). The loss of 
functionality in distal muscles may result in inability to perform manual tasks, such as threading a 
needle or opening doors with keys. Weakness in tibialis anterior and other muscles of the lower 
extremities causes difficulties in walking, causing a steppage gait (Welander, 1951). Although 
neuronal involvement has been suggested earlier (Borg et al. 1987), there is no actual evidence of it 
(Jaakko Sarparanta, personal communication). 
 
The disease progresses slowly: patients are most often able to live normal lives and are rarely 
wheelchair bound as a result of the disease. The patient’s life expectancy does not change following 
a diagnosis (Welander 1951). 
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Homozygotes for the mutation are rare, and more severely affected by the disease (Welander 1951). 
Homozygotes show symptoms earlier, at an average age of 30. In homozygotes both distal flexors 
and proximal muscles become involved within 5 to 10 years after onset. The course of the disease is 
more rapid and aggressive in these patients, who often lose their ability to walk during the 
progression of the disease, and eventually become wheelchair bound by the age of 50 (Welander 
1951, Åhlberg et al. 1999).  
 
As for most other muscular dystrophies, there is no pharmacological treatment for WDM, although 
patients may receive physiotherapy or be advised to increase strength through low to moderate 
intensity strength and aerobic training (Ansved, 2001). 
 
5.2. HISTOPATHOLOGY	  
Histopathology of WDM muscle reveals a typical chronic myopathic muscular tissue with varying 
fiber size, split fibers, internal nuclei and fiber atrophy affecting both slow and fast fibers. Rimmed 
vacuoles are present to a variable degree in both normal-sized and atrophic fibers (Åhlberg et al. 
1994). 
 
Autophagic vacuoles can be observed by electron microscopy in WDM muscle (figure 6). 
Autophagic vacuoles are ultra-structural correlates to rimmed vacuoles. In association to them, 
tubulofilamentous inclusions are found in the sarcoplasm and occasionally in nuclei. Other reported 
abnormalities are fingerprint bodies, honeycomb structures, accumulations of Z-disc material, Z-
disc streaming and changes in mitochondria (Borg et al.  1998). 
 
 
Figure	  6.	  Histopathological	  changes	  in	  soleus	  (A	  and	  C)	  and	  tibialis	  anterior	  (B)	  in	  a	  patient	  with	  WDM.	  In	  all	  pictures	  
atrophic	  fibers	  can	  be	  seen.	  In	  addition,	  rimmed	  vacuoles	  (shown	  by	  the	  arrows)	  can	  be	  seen	  in	  A	  and	  C.	  The	  bar	  in	  C	  
represents	  50µm.	  (Adapted	  from	  Åhlberg	  et	  al.	  1994)	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5.3. GENETICS	  
One common mutation is found in all known WDM cases in Sweden and Finland. It is a missense 
mutation c.1150G>A (RefSeq NM_022173.2) in a gene called TIA1 cytotoxic granule-associated 
RNA-binding protein (TIA1, also known as T-cell intracellular antigen 1, OMIM *603518) 
(Hackman et al. 2013). The mutation is located in a prion related domain in the 13th and last exon of 
the gene, and causes the change p.E384K (RefSeq NP_071505.2) in the third last amino acid in the 
protein product TIA1 (Hackman et al. 2013). Heterozygotes develop the typical symptoms for 
WDM, while homozygotes are affected more severely. The gene is thus described as semi-dominant 
(Welander 1957, Åhlberg et al. 1999, Hackman et al. 2013). 
 
The disease has been recorded only in Sweden, Finland and Great Britain (one family) (Hackman et 
al. 2013). The prevalence of the disease is highest in Sweden, where 1/10,000 inhabitants are 
affected. The prevalence is higher in the central and northern parts of the country, where it can 
reach numbers as high as 1/70 (Åhlberg et al. 1999). In Finland, the estimated prevalence is 
>2/100,000 (Bjarne Udd, personal communication). The original appearance of the mutation has 
been estimated to date back circa 1050 years (Klar et al. 2013). 
 
The causative mutation was found by targeted high-throughput and Sanger sequencing of the 
candidate WDM region by Hackman et al. 2013 and was further confirmed to be the pathogenic 
change by studying the stress response in cell cultures by immunofluorescence microscopy 
(Hackman et al. 2013). 
 
TIA1	   
TIA1 cytotoxic granule-associated RNA-binding protein (OMIM *603518, RefSeq NM_022037), 
also known as T-cell intracellular antigen 1, is a cytoplasmic protein with multiple functions in 
splicing regulation, RNA metabolism and protein expression. It is associated with granule 
formation, and expressed in cytolytic lymphocytes (CTLs) and natural killer cells (Anderson et al. 
1990). There are two splice isoforms of TIA1, which differ by a 33bp/11aa sequence that is 
excluded in exon 5 in TIA1b. There is no significant recorded difference in the functionality of the 
two transcript products (Hackman et al. 2013). 
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TIA1's domain structure as well as many of its functions is shared with its close homologue TIAL1 
(TIA1-like, also known as TIAR, TIA1-related protein). TIA1 and TIAL1 are identical to ~80% in 
their amino acid sequences and ~50% in the prion-related domains (PRDs) (Kawakami et al. 1992). 
 
The 13 exons of TIA1 span over 46 kb of genomic DNA (Kawakami et al. 1994). The gene product, 
the TIA1 protein, contains three RNA-binding domains (RNA recognition motifs, RRM). These are 
followed by a C-terminal glutamine-rich PRD (Tian et al. 1991). The two splice variants occur as a 
result of alternative splicing. The longer isoform TIA1a (splice variant 2; RefSeq NP_071505) is 
386 amino acids long, with a theoretical molecular weight of 43.0 kDa. In the shorter variant TIA1b 
(splice variant 1; RefSeq NP_071320), an exclusion of 11 amino acids is made in the exon 5 
between the two first RRMs. The resulting protein is 375 amino acids long with a theoretical weight 
of 41.8 kDa (Tian et al. 1991, Kawakami et al. 1994). The TIA1 protein structure is visualized in 
Fig. 7, and the sequence including variants discussed in this thesis is found as supplement 3. 
 
The localization of TIA1 in unstressed cells is primarily nuclear, although there is a constant 
exchange (shuttling) of the protein between the nucleus and the cytoplasm (Zhang et al. 2005). As a 
response to cellular stress, TIA1 is rapidly moved to the cytoplasm. The exact mechanism behind 
the relocation has not been reported, but it has been suggested that it would follow as a result from 
inactivation of nuclear import (Kedersha et al 1999). 
 
 
 
 
Figure	  7.	  The	  TIA1	  protein	  includes	  three	  different	  RNA-­‐binding	  motifs	  (RRM1-­‐3),	  which	  are	  followed	  by	  a	  glutamate-­‐
rich	   prion-­‐related	   domain	   (PRD).	   The	   TIA1a-­‐specific	   11aa	   region,	   excluded	   in	   the	   TIA1b	   isoform,	   is	   shown	   in	   grey.	  
Reprinted	  with	  permission	  from	  Jaakko	  Sarparanta.	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The overexpression of TIA1 in cell cultures leads to stress granule formation (discussed under 
6.1.1. Composition and mechanism of formation), but also a simultaneous decrease in the 
expression of reporter genes. However, when the PRD domain is isolated and expressed in cells, 
TIA1 and TIAR binding cytoplasmic microaggregates are formed and a simultaneous increase in 
co-transfected reporter genes is noticed (Kedersha et al. 1999). 
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6. CELLULAR	  STRESS	  
In the event of a change in the cell's environment (stress), it has to either adapt to the new 
conditions or give up. Depending on the type of stress, the cell can thus either activate an apoptotic 
pathway leading to cell death, or induce survival mechanisms (Arimoto et al. 2008). The survival 
mechanisms often come at the cost of loss of functions that are not needed for survival. Changes in 
the environment that lead to the so called stress response include, but are not restricted to, changes 
in temperature, oxidative stress, ischemia, viral infections and UV radiation (Anderson and 
Kedersha 2008, Arimoto et al. 2008, Hofmann et al. 2012). 
 
The eukaryotic cell has a variety of different proteins, which monitor changes in its environment. 
These proteins are also responsible of starting the stress response cascade when needed. Depending 
on what kind of stress the cell is exposed to, different pathways are activated as a response to the 
stress. The first reaction is often partial or complete translational arrest. The translational arrest 
saves the cell energy, which can then be reallocated and focused to processes that repair molecular 
damage caused by the stress (Anderson and Kedersha 2008). It has been shown that the decrease in 
protein synthesis that follows translational arrest is potentially selective, and that the synthesis of 
certain proteins increases under stressful conditions (Kawai et al. 2004). However, stress responses 
always lead to a reaction in the translational machinery and thus in the proteome of the cell 
(Anderson and Kedersha 2008). 
 
In mammalian cells the environmental changes are monitored by five different eIF2α kinases: 
protein kinase R (PKR), pancreatic eIF2α-kinase (PERK), General control nonderepressible 2 
(GCN2), heme-regulated eIF2α kinase (HRI), and Z-DNA. These kinases all react to mainly 
different, but partially the same changes, as indicated in Table 3. The kinases' task is to start the 
cascade that leads to translational inhibition. The mechanism is discussed under section 6.2. 
Composition and mechanism of formation. 
 
Table	  3.	  The	  five	  kinases	  in	  charge	  of	  inducing	  the	  stress	  response.	  ER	  =	  endoplasmic	  reticulum.	  
Kinase	   Activated	  by	   Reference	  
PKR Viral infection, heat shock, UV radiation Srivastava et al. 1998 
PERK Accumulation of unfolded proteins in ER Harding et al. 1998, Harding et al. 2000, Hoffman et al. 2000 
GCN2 Starvation (decreased amount of free amino acids) Wek et al. 1995 
HRI Oxidative stress McEwen et al. 2005 
Z-DNA Immunological response to viral infection Wek et al. 1995 
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6.1. STRESS	  GRANULES	  
Stress granules (SGs) are functional by-products of mRNA metabolism observed in yeast, plant and 
metazoan cells. SGs are formed by stalled translation pre-initiation complexes that aggregate with 
different proteins in the event of stressful conditions (Anderson and Kedersha 2002). 
 
 SGs are observed in cells that have been exposed to environmental changes that induce the cell’s 
survival mechanisms – stress (Fig. 8). In the event of stress, eukaryotic cells reprogram their 
translational machinery. By reducing the global translation and thus avoiding translating 
unnecessary proteins, cells reallocate their resources in order to selectively express proteins needed 
for viability and cellular survival under the new or changing conditions (Kedersha et al. 2005, 
Hofmann et al. 2012). 
  
 SGs are highly dynamic, in contrast to static ribonucleoprotein (RNP) aggregates. There is a 
constant exchange of proteins and mRNA between SGs and the cytosol, often referred to as 
shuttling. Fluorescence recovery after photobleaching (FRAP) studies have shown, that protein 
components and reporter mRNAs may reside in SGs from seconds to minutes. One of the most 
mobile protein components is TIA1, which shows a ~90% fluorescence recovery within 10 seconds 
of bleaching (Kedersha et al. 2000, Hackman et al. 2013).  
 
 
Figure	   8.	   Immunofluorescence	   image	   of	   HeLa	   cells	   transfected	   with	   green	   fluorescent	   protein	   (GFP)	   tagged	   TIA1	  
constructs.	  Here,	  the	  TIA1a	  wild	  type	  and	  p.E384K	  mutation	  without	  stress	  inducing	  treatment	  are	  shown	  side-­‐by-­‐side	  
with	   cells	   that	   have	   been	   treated	   with	   sodium	   arsenite	   to	   induce	   a	   stress	   response.	   TIA1a	   is	   seen	   as	   clear	   green	  
granules	  around	  the	  nucleus.	  The	  arsenite	  treated	  cells	  show	  a	  significant	  increase	  in	  stress	  granule	  amount	  compared	  
to	  the	  non-­‐treated	  cells	  (Adapted	  from	  Hackman	  et	  al.	  2013).	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6.1.1. COMPOSITION	  AND	  MECHANISM	  OF	  FORMATION	  
A correct regulation of gene expression is dependent on a meticulous control of the mRNA 
translation, localization and degradation, especially in situations such as during stress or 
embryogenesis (Buchan et al. 2013). 
 
SGs are formed by stalled 48S-preinitiation complexes, which form cytoplasmic complexes 
(granules) with different proteins (Anderson and Kedersha 2008). The main components beyond the 
stalled preinitiation complexes are the early initiation factors eIF4E, eIF3, eIF4A, eIFG and poly-A-
binding protein 1 (PABP). The granules also contain RNA-binding proteins that play a role in the 
regulation of mRNA translation and decay, as well as other proteins involved in the mRNA 
metabolism. SGs have also been found to contain proteins related to the regulation of cell signaling 
pathways (e.g. TRAF2; Hofmann et al. 2012, Kim et al. 2005). 
 
The composition of the granules varies both over time and depending on which kind of stress 
induces their assembly (Anderson and Kedersha 2008). Far over one hundred different protein 
coding genes have been found to play a role in the composition of stress granules and the regulation 
of their formation (Buchan et al. 2013). The metabolism of mRNA can thus be assumed to depend 
on a largely unknown, vast and intricate network of different kinds of interactions between different 
genes and proteins (Buchan et al. 2013). Some of the identified proteins in association to SGs are 
shown in Table 4. 
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Table	  4.	  SG-­‐associated	  proteins	  (adapted	  from	  Anderson	  and	  Kedersha,	  2008)	  
Protein	   Relevant	  binding	  partners	   Nucleates	  SGs?	   Known	  functions	  
Ago2 FXR1, RISC Yes RNAi slicer 
APOBEC3G ? No Antiviral response 
Ataxin-2 PABP-1 No Translation 
Caprin-1 G3BP Yes Cell growth 
CPEB RCK, eIF4E, FXR1 Yes mRNA silencing 
DIS1 eIF3h Yes Unknown 
eIF3 40S, eIF4G ? Translation 
eIF4E CPEB, smg, eIF4G, 4ET No Translation 
eIF4G eIF4E, eIF3, PABP-1 ? Translation 
FAST TIA-1 Yes Translation 
FMRP and FXR1 Ago2, RISC Yes Translation 
FBP and KSRP TIA-1 No RNA decay 
G3BP Caprin Yes Ras signalling 
HuR ? No RNA stability 
IP5K ? Yes Signaling 
Lin28 ? ? Development 
LINE1 ORF1p ? Yes Transposon 
MLN51 Exon junction No Splicing 
PABP-1 eIF4G, eIF3, ataxin-2 No Translation, stability 
DDX6 (p54) HedIs (GE-1), TTP Yes mRNA decay 
Plakophilin G3BP FXR1 No Adhesion 
PMR1 TIA1 No mRNA decay 
Pumilio 2 ? Yes mRNA silencing 
Rap55 ? ? mRNA silencing 
Rpb4 ? ? Transcription 
SRC3 TIA1 No Transcription 
Staufen ? No mRNA silencing 
SMN SMN complex Yes RNP assembly 
TIA1 and TIAR FAST, SRC3, PMR1, FBP Yes mRNA silencing 
TRAF2 eIF4G No Signaling 
TTP and BRF-1 DDX6 (p54) Yes mRNA decay 
YB-1 ? ? Cold-shock RNA binding protein 
ZBP1 ? No Localization 
 
 
 
Stress granule assembly is known to happen according to two different principles: 
1) Translational silencing, which leads to the presence of non-translating RNA, and 
2) dimerization or aggregation of mRNP-binding proteins 
 
The SG assembly and stress-induced translational arrest is known to be initiated by phosphorylation 
of translation initiation factor eIF2α (Kedersha et al. 2005), which is mediated by five stress 
monitoring kinases (HRI, PERK, GCN2, PKR and Z-DNA kinase) in mammals (Anderson and 
Kedersha, 2008). In normal cases, eIF2α brings the translational initiator tRNAiMet to the 40S 
ribosomal unit (Holick and Sonenberg, 2005).  
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Once phosphorylated, eIF2α can no longer dissociate from eIF2B, its guanosine diphosphatase 
(GDP) exchange factor. This in turn prevents recharging of the eIF2α-GTP-tRNAiMet ternary 
complex, which is needed to initiate protein translation. mRNP-binding proteins that are present in 
the cytosol (such as TIA1) are then bound to the stalled translation initiation complex. Due to the 
ability of the protein to bind both RNA and protein, the stalled translation initiation complexes bind 
with each other and form complexes (Anderson and Kedersha 2008). The phosphorylation of eIF2α 
thus leads to stalled translation pre-initiation complexes that aggregate in the cytosol: SGs 
(Kedersha et al. 1999). This mechanism is shown in Fig. 9. 
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Figure	  9.	   The	  mechanism	  of	   stress	  granule	   formation.	   In	  normal	   cells	  eIF2α-­‐GDP	   is	  phosphorylated	   to	  eIF2α-­‐GTP.	  A	  
translation	  complex	  is	  then	  built	  by	  eIF2α-­‐GTP,	  the	  ribosomal	  40S	  subunit	  initiation	  factors	  included	  and	  the	  tRNAiMet	  
translation	  initiator.	  The	  initiation	  factors	  leave	  the	  complex	  when	  bound,	  and	  the	  ribosomal	  60S	  subunit	  can	  bind	  to	  
the	   complex	   and	   the	   translation	   is	   initiated.	   In	   the	   case	   of	   stress,	   a	   stress	  monitoring	   kinase	   (PKR	   in	   the	   example)	  
responds	   to	   the	   environmental	   stress	   by	   phosphorylating	   eIF2α,	  which	   prevents	   it	   from	  dissociating	   from	   the	  GDP	  
exchange	  factor	  eIF2B.	  This	  allows	  TIA1	  to	  bind	  to	  the	  translation	  initiation	  complex.	  TIA1	  inhibits	  the	  initiation	  factors	  
from	   dissociating	   the	   complex,	   and	   thus	   the	   ribosomal	   60S	   subunit	   is	   unable	   to	   bind	   to	   the	   complex.	   TIA1	  
subsequently	  aggregates	  with	   itself	   in	  other	  stalled	   translation	   initiation	  complexes	  and	  stress	  granules	  are	   formed.	  
(Adapted	  from	  Anderson	  and	  Kedersha,	  2008)	  
Legend:	  
	  
1-­‐5: Early initiation factors (eIFs) 
40S: The small ribosomal subunit 
60S: The large ribosomal subunit 
AUG: Start codon 
GDP: Guanosine diphosphate 
GTP: Guanosine triphosphate  
TIA1: TIA1 protein 
 
tRNA	  Met depicted as an L-formed 
strand 
mRNA depicted as long strand with a 
poly-A tail 
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The common components included in all stress granules are the stalled initiation complexes, that are 
still bound to the mRNA and that have been moved from the degraded polysomes to the granules. 
The composition of stress granules does however vary to some degree depending on a number of 
factors, such as what kind of stress induces their formation, in which kind of cell they are formed 
and also how long the response has lasted (Anderson and Kedersha 2008). 
 
Furthermore, the different components included in stress granules are divided into a couple of 
categories. Stress granules can contain a number of different mRNA binding proteins, which have 
roles in translational silencing and mRNA stability. These proteins can function as markers for 
stress granules, but are not necessarily present in all stress granules. An example of such a protein is 
TIA1 (Anderson and Kedersha 2008). 
 
Another group of stress granule related proteins are the proteins that regulate the RNA metabolism 
in other ways than controlling the translation or degradation of mRNA. Proteins involved in 
splicing, RNA modifications, and RNA localization belong to this group. These proteins have been 
noticed to cause stress granule formation when over expressed in cell cultures (Anderson and 
Kedersha 2008). TIA1 represents this group of proteins as well (Gilks et al. 2004). 
 
It has been proposed, that the formation of stress granules is also at least somewhat dependent of the 
cytoplasmic skeleton. Cells exposed to both SG inducing and microtubule-depolymerizing 
treatments (arsenite and vinblastine respectively) produce no SGs, whilst control cells treated with 
only arsenite assemble stress granules as expected. This suggests the involvement of microtubule as 
a facilitator of the stress granule assembly (Ivanov et al. 2003). 
 
If the environmental factors return towards a more favorable situation for the cell and the stress 
response in silenced, the stress granules are dissolved. In cell cultures the granules are degraded in 
minutes, when optimal cell conditions are restored after a stress-inducing treatment. Before they are 
degraded, they seem to accumulate into fewer but larger granules, which are then rapidly degraded 
(Buchan et al. 2013). It is still partly unknown on what basis the cell determines how the stress 
granule components will be degraded. To some extent the translation is resumed from the point at 
which it was stopped in the translation initiation complexes, but some complexes are degraded to 
their very basic building blocks (Buchan et al. 2013). 
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It has furthermore been shown that cells dispose of SGs to some degree by autophagy. The granules 
are targeted to vacuoles, which degrade them (Buchan et al. 2013). 
 
6.1.2. THE	  ROLE	  AND	  IMPORTANCE	  OF	  TIA1	  AND	  STRESS	  GRANULES	  
The WDM causing mutation was studied by transfecting HeLa cells (derived from human cervical 
cancer) with a GFP-tagged TIA1-protein (Hackman et al. 2013), as it causes the formation of stress 
granules when over expressed (Gilks et al. 2004). The cells were studied with immunofluorescence 
microscopy. Cells that were transfected with the WDM-mutation p.E384K showed a 10-20% 
increase in both stress granule size and number (Hackman et al. 2013). 
 
The mutated glutamate residue is highly conserved in all tetrapodes. In addition, it is located in the 
protein’s PRD-domain, which plays a role in its ability to self-aggregate (Hackman et al. 2013). 
 
Environmental factors have been proposed to affect the development of disease in Welander Distal 
Myopathy. Hofmann et al. observed an increased number of stress granules in several mammalian 
cell lines treated with cold shock compared to cells kept in 30°C, using eIF3B as a marker 
(Hofmann et al. 2012).  
 
Their findings are of interest due to the nature of WDM; the symptoms start in the distal muscles of 
the extremities, the temperature of which is often significantly lower compared to the body’s core 
temperature. Furthermore the disease is encountered only in countries with relatively cold climates, 
which could hypothetically be caused by the fact that people living in warmer climates do not 
express symptoms despite harboring the causative mutation, due to not being exposed to cold 
climates.  
 
In a number of patients with WDM-like symptoms lacking the c.1150G>A mutation, a c.1070A>G 
change has been found (Hackman et al. unpublished). This c.1070A>G change has earlier been 
reported as a polymorphism (rs116621885), and it causes an amino acid change from asparagine to 
serine in the 357th amino acid (p.N357S). The change in question is located 80 base pairs upstream 
from the WDM-causing mutation in the same PRD. Therefore, the p.N357S-change could 
theoretically affect the predisposition to increased formation of stress granules. For the amino acid 
sequences for the proteins encoded by the different TIA1 variants, refer to supplement 3. 
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As the case with TIA1 and WDM shows, stress granules are potential pathological indicators to 
other degenerative diseases as well. Mutations in different stress granule related proteins lead to 
different kinds of changes in stress granule size, number and dynamics. Besides being pathological 
indicators, stress granules have also been suggested to contribute to the actual pathogenesis of 
diseases (Anderson and Kedersha 2008). 
 
The Fragile X syndrome is caused by mutations in the gene coding for fragile X mental retardation 
protein (FMRP). Patients with Fragile X have immature dendritic spines as a probable result of 
malfunctioning translational machinery. FMRP is an RNA-binding protein, and plays a role in the 
synthesis of synaptic proteins. It has been suggested that a malfunctioning FMRP protein could 
contribute to the deficient development of the synaptic dendrites, and in addition cause 
accumulation of SGs. In studies, FMRP is also seen as a component of the mRNA granules (Antar 
et al. 2005). 
 
Radiation therapy of cancer tumors causes the tumor cells to express a protein called hypoxia 
inducible factor 1 (HIF-1). HIF-1 induces the production of mRNA that codes for endothelial 
survival factors. Endothelial cell damage is a strong indicator of the efficiency of the radiation 
therapy. The transcripts that HIF-1 induces can though be silenced by stress granules, which causes 
a larger amount of damage on the endothelial cells and thus reinforces the efficiency of the radiation 
therapy (Moeller, 2004). 
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7. AIMS	  OF	  THE	  STUDY	  
The study can be divided into two parts: 
 
I) SUBPROJECT	  I:	  SNP	  p.N357S	  
The objective of the experiment was to explore the effects of the p.N357S-change in TIA1 and 
evaluate the possibility of it being a pathogenic mutation. The p.N357S change was induced in 
pEGFP-TIA1 constructs by mutagenic PCR, transfected into and expressed in HeLa (human 
cervical cancer) and 293T (human embryonic kidney) cells. The cells were then studied by the same 
methods as used to confirm the pathogenesis of the p.E384K WDM-causing mutation: expression 
and solubility tests, CellInsight spot count analysis and FRAP (Hackman et al. 2013). 
 
The hypothesis was that p.N357S TIA1 would behave differently from the wild-type, and the 
expectation was to see similar changes as with the Welander causing mutation p.E384K, as the 
phenotype is very similar. It was thus expected, that the p.N357S transfected cells would display a 
larger amount of stress granule compared to the cells transfected with the wild type gene. In 
addition, it was expected for the p.N357S transfected cells to express stress granules that, alike to 
p.E384K transfected cells, recover slower in FRAP studies. 
 
II) SUBPROJECT	  II:	  THE	  EFFECT	  OF	  COLD	  SHOCK	  ON	  STRESS	  GRANULES	  
The objective of the experiment was to test whether HeLa cells transfected with pEGFP-TIA1 
p.E384K constructs expressed different levels of stress granules compared to their wild-type 
counterparts when treated with cold shock, and, ultimately, whether cold shock could induce a 
pathological amount of stress granules in the cells. HeLa cells were transfected with the selected 
constructs, treated with cold shock and imaged and analyzed using CellInsight platform. 
 
The hypothesis was that p.E384K TIA1 would show an increased amount of stress granules as 
compared to the wild-type due to the SNPs previously shown behavior in arsenite treated cell 
cultures (Hackman et al. 2013).  
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8. MATERIAL	  AND	  METHODS	  
8.1. CELL	  CULTURE	  CONDITIONS	  AND	  METHODS	  (I	  &	  II)	  
HeLa cells (ATCC, Manassas, VA, USA) were cultured at 37ºC, 5% CO2 in Dulbecco modified 
Eagle medium (Life Technologies Inc Gibco/Brl Division, Grand Island, NY, USA) with 10% fetal 
calf serum, GlutaMAX (Invitrogen/Life Technologies, Carlsbad, CA, USA) and 
penicillin/streptomycin. Transfections were done with FuGENE 6 (Promega Corporation, Madison, 
WI, USA), according to the manufacturer’s instructions. 
 
The pEGFP-TIA1a and b wild-type and p.E384K constructs used in transfections were received 
from Jaakko Sarparanta, and were identical to those used in the Hackman et al 2013 paper. The 
pEGFP-TIA1a and b p.N357S constructs were created by mutagenic PCR in the pEGFP-TIA1 wild-
type constructs, the process of which is described under section 8.5. Creation of pEGFP-TIA1 
p.N357S plasmid. 
 
8.2. CELLINSIGHT	  HIGH	  CONTENT	  IMAGE	  ANALYSIS	  (I	  &	  II)	  
HeLa cells were seeded on 24-well plates at a density of 75k cells/well. The cells were then 
transfected with GFP-TIA1 constructs. Cells were treated with 500 µM sodium arsenite (Thermo 
Fisher Scientific, Waltham, MA, USA) or control medium 18h after transfection for 45 minutes, 
after which they were fixed with 4% paraformaldehyde (PFA)/phosphate-buffered saline (PBS). 
The cells were permeabilized with 0.2% Triton X-100 in PBS and stained with Hoechst to label the 
nuclei. 
 
The cells were imaged by using the CellInsight instrument (Thermo Fisher Scientific). Per well, 100 
images were captured using a 10×/NA 0.3 objective and fixed exposure times through two 
channels. The images were analyzed using the automated image analysis software SpotDetector V4 
Bio Application in vHCS Scan 6.2.3 (Thermo Fisher Scientific).  
 
Based on mean fluorescence intensity of the entire cell, cells expressing moderate levels of TIA1 
were selected for further analysis. The fluorescent spots (stress granules) that fulfilled pre-
determined criteria of size, shape and intensity from a selected region of interest surrounding the 
nucleus were analyzed (Fig. 10). The results were normalized to the mean of the control wells 
(untreated wild-type) on the same plate. 
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Figure	  10.	  Demo	  of	  CellInsight	  analysis	  principle,	  showing	  the	  region	  of	  interest	  (ROI)	  boundaries	  around	  the	  nuclei	  
and	  the	  cells	  in	  green	  and	  the	  counted	  spots	  in	  red.	  (Adapted	  from	  Hackman	  et	  al.	  2013)	  
 
8.3. IMAGE	  PROCESSING	  AND	  ANALYSIS	  (I	  &	  II)	  
Images were processed and analyzed using a variety of different software: Adobe Photoshop CS4 
Extended 11.0.2 (Adobe Systems Inc., San Jose, CA, USA), GNU Image Manipulation Program 
(various versions, http://www.gimp.org), ImageJ (various versions, US National Institutes of 
Health, Bethesda, MD, USA), ImageStudioLite 5.0.21 (LI-COR Biosciences, Lincoln, NE, USA) 
LSM 510 Meta 3.2 software (Carl Zeiss MicroImaging GmbH, Göttingen, Germany), Odyssey 
Infrared Laser Imaging System (LI-COR Biosciences), and vHCS Scan 6.2.3 software (Thermo 
Fisher Scientific). 
 
8.4. STATISTICAL	  ANALYSIS	  METHODS	  (I	  &	  II)	  
Statistical analyzes for CellInsight and FRAP data were performed in Microsoft Excel 14.1.4. 
(Microsoft, Redmond, WA, USA) and IBM SPSS Statistics (various versions, International 
Business Machines Corporation, Armonk, NY, USA).  
 
The spot count data for each group was pooled and normalized according to the mean of untreated 
wild-type relative spot counts. Significance levels (p values) of the spot count differences were 
determined according to the 2-tailed Mann-Whitney U-test or an independent sample T-test where 
the former could not be implemented. The methods are used to determine the significance of the 
difference between two independent data groups that consist of ordinal responses. 
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8.5. CREATION	  OF	  EGFP-­‐TIA1	  p.N357S	  PLASMID	  (I)	  
A mutagenic PCR was executed using existing pEGFP-TIA1a and pEGFP-TIA1b plasmids 
(Hackman et al. 2013) as templates.  
 
The mutagenic primers were designed manually by determining the position of the wanted point 
mutation in the plasmid using the sequence of the gene and the plasmid (Ensemble and Invitrogen, 
respectively). The forward primer included a mismatch nucleotide at the wanted position to induce 
the mutation. The melting temperatures of the primers were matched using the Tm calculator of 
Life Technologies. The primers were ordered from Sigma Aldrich (St. Louis, MO, USA). 
 
The mutagenic PCR was executed using Phusion™ High-Fidelity DNA Polymerase (Thermo 
Scientific). For the plasmid map and PCR conditions including primer sequences, see supplement 1 
and 2 respectively. 
 
The PCR products were confirmed by running them in a 0.8% agarose gel (110 V, 45 min), purified 
using NucleoSpin Plasmid (Machery-Nagel, protocol 5.5. Support protocol Plasmid (NoLid) and 
NucleoSpin Plasmid Quick Pure Plasmid Clean-up and 5.1. Isolation of high-copy plasmids from E. 
coli, from step 5 onward). Purified PCR products were ligated with Quick T4 DNA Ligase (New 
England BioLabs, Ipswich, MA, USA). The reaction mix is shown in Table 4. 2,5 µl of ligation 
mix per construct was transformed into 25 µl of OneShot TOP10 Chemically Competent E. coli 
cells (Invitrogen/Life Technologies) according to the corresponding protocol, and plated on 
kanamycin containing LB agar plates. 
	  
Table	  4.	  Ligation	  reaction	  mix	  for	  mutagenic	  pEGFP-­‐TIA1	  p.N357S	  PCR	  products	  
Reagent	   Amount/reaction	  
PCR product 1 µl 
Water 9 µl 
Quick Ligase Buffer (2x) 10 µl 
Quick T4 DNA Ligase 1 µl 
Σ 21 µl 
  
 
Pure liquid cultures were made from the transformant colonies, from which plasmids were extracted 
using Fermentas NucleoSpin (protocol for high-copy plasmid preps from E. coli). The samples were 
then digested with EcoRI Fast-Digest (Fermentas, Vilnius, Lithuania) for 10 min at 37ºC and run in 
a 0.8% agarose gel (120 V, 35 min) to confirm successful ligation. Confirmation of successful 
mutagenesis was done by sequencing (FIMM). 
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Successfully mutagenized pEGFP-TIA1a and pEGFP-TIA1b samples along with the original wild 
type pEGFP-TIA1a and pEGFP-TIA1b constructs were digested with BamHI and HindIII (New 
England BioLabs) for 15 min at 37ºC and 20 min at 80ºC for HindIII inactivation. The samples 
were then run in a 0.8% agarose gel (110 V, 35 min). The bands of the mutagenic inserts and the 
wild type vector were extracted from the gel using a GeneJet Gel Extraction Kit (Fermentas). 
 
The purified samples were ligated with Quick T4 DNA Ligase (New England BioLabs) and 
transformed into 5α chemically competent E. coli (New England BioLabs). Ligation of insert was 
confirmed by restriction analysis with BamHI and HindIII (New England BioLabs) as above and 
the samples were sequenced (FIMM) to ensure correct sequence (see supplement 4). 
 
Midi-preps were made of all correct transformants using a HiSpeed Plasmid Midi Kit (Qiagen, 
Hilden, Germany). The yield and purity was checked with spectrophotometry at wavelength 260 nm 
and 280 nm using NanoDrop 1000 3.6.2. (Thermo Scientific) 
	  
8.6. INDUCTION	  OF	  STRESS	  GRANULES	  BY	  ARSENITE	  TREATMENT	  (I)	  
Stress granule assembly was induced by generating oxidative stress conditions by treating cultured 
HeLa cells with 500 µM sodium arsenite in normal media for 45 minutes before cell fixation. For 
control cells, the old media was changed for fresh media but no further steps were taken. 
 
8.7. EXPRESSION	  AND	  SOLUBILITY	  TESTS	  (I)	  
The expression and solubility tests were performed to assess whether the mutation would affect the 
expression or the solubility of the protein. It has earlier been concluded that the p.E384K mutation 
does not affect these features (Hackman et al. 2013), but it was included in the analysis nonetheless. 
 
The tests were performed in HeLa and 293T cells. HeLa cells were also used for the CellInsight 
stress granule quantification analysis and FRAP. In addition, this worked as a transfection test of 
the produced constructs. 293T cells are significantly more efficient than HeLa cells at over-
expressing transfected proteins and thus possible differences in expression can be more prominent 
in them. Due to these differences in qualities between the two cell lines, the test in HeLa was 
regarded a transfection and expression test, whilst the test in 293T was used to assess protein 
features. 
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Both cell lines were transfected with isoforms a and b of wild-type, p.E384K and p.N357S TIA1. 
The same protocol was used for both cell lines. 
 
The cells were seeded on 2×6–well plates and transfected with GFP-tagged TIA1 constructs. The 
cells were allowed to express the proteins for 24 h. The cells were then washed with PBS, 
resuspended in 1 ml of PBS and transferred to eppendorf tubes. The cells were pelleted (10 min, 
500 g), the supernatant was removed and the pellet was chilled on ice. The pellet was then 
resuspended in radioimmunoprecipitation assay (RIPA) buffer (50 mM Tris-HCl pH 8.0, 150 mM 
NaCl, 1% Triton X-100, 0.1% SDS, 0.5% sodium deoxycholate) containing 1:100 protease inhibitor 
(HaltTM Protease Inhibitor Cocktail, Thermo Fisher Scientific) and incubated on ice for 15min. The 
sample was vortexed twice during the incubation.  
 
The cells were pelleted (15 min, 13000 g) and a 10 µl sample was taken from the supernatant. 130 
µl of 2× SDS Sample Buffer and 3.3 µl of β-mercaptoethanol was added.  
 
The pellet was washed and resuspended in RIPA buffer (without protease inhibitor) and centrifuged 
(15 min, 13000 g). The supernatant was removed and 100 µl of 1× SDS Sample Buffer and 1.2 µl β-
mercaptoethanol was added. The samples were incubated at 65°C for 30 min. Both the supernatant 
and the pellet samples were then boiled for 5 min at 95°C.  
 
The samples were run in a sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) 
(Bio-Rad) and blotted to a nitrocellulose membrane using Bio-Rad’s Trans-Blot Turbo Blotting 
System. The membrane was blocked with 5% milk in PBS for 1 h at RT, and then incubated in 1% 
milk in PBS with 0.1% Tween-20 (PBST) and primary antibodies over night. The antibodies used 
were against GFP (FL) Rabbit polyclonal IgG (SC8334, Santa Cruz Biotechnology, Inc., Santa 
Cruz, CA, USA) and α-tubulin (AB 6160, YL1/2, Abcam plc, Cambridge, UK). 
 
The membrane was washed with PBST buffer repeatedly over the course of 1 h to ensure removal 
of all non-bound primary antibodies. The membrane was then incubated in 1% milk with 0.1% 
Tween-20, 0.01% SDS and secondary antibodies for 1 h at RT. The secondary antibodies used were 
Alexa Fluor 680 anti-rat IgG (H+L) (A21096, Invitrogen) and IRDye 800CW goat anti-Rabbit IgG 
(H+L) (926-32211, Li-COR Biosciences, Lincoln, NE, USA). The membrane was then washed with 
PBST and finally with PBS and scanned using Odyssey Infrared Laser Imaging System (LI-COR 
Biosciences). 
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The membranes of the expression and solubility tests were analyzed with ImageJ and Microsoft 
Excel. A 30×30 pixel or 130×30 pixel square was drawn around each band for HeLa and 293T 
samples respectively. The returned intensity curve was measured by manually selecting a horizontal 
baseline for the curve, excluding possible background, as objectively as possible. The area under 
the curve was then measured, returning a value reflecting the intensity of the band. 
 
The values were normalized by issuing a factor to each sample based on the intensity of the tubulin 
band as compared to the mean of all tubulin bands. The bands representing GFP were then 
multiplied by this factor and then compared with the normalized tubulin value. 
 
The values were assembled in Microsoft Excel and p values were calculated by a independent 
samples T-test in SPSS. 
 
8.8. FLUORESCENCE	  RECOVERY	  AFTER	  PHOTOBLEACHING	  (I)	  
GFP-TIA1a wild-type, p.E384K and p.N357S transfected HeLa cells were seeded on Lab-Tek II 
chambered cover slides (Nunc A/S, Roskilde, Denmark) in phenol-red-free medium. Cells were 
treated with 500 µM sodium arsenite or control medium 18h after transfection to induce stress 
granule formation. The cells were analyzed with FRAP at 37ºC, 5% CO2 within 55 minutes after 
stress induction. 
 
The FRAP measurements were performed with an LSM510 Duo confocal microscope equipped 
with an LD C-Apochromat 40×/NA 1.1 water immersion objective (Carl Zeiss Micro-Imaging) The 
instrument zoom factor was set to 20× and the frame size to 90×90 pixels. Inside this frame, a 
circular target of 8 pixels (equivalent of 1 µm) was selected and centered on a stress granule. The 
selected area was bleached with three laser lines (405 nm, 458 nm, 488 nm) by point bleaching. For 
each analyzed granule, a time series of 40 frames was captured – 5 frames were captured before 
bleaching and 35 after. The frames were taken with maximum acquisition speed at intervals of 250 
ms.  
 
The resulting images were analyzed in ImageJ (version 1.48, http://imagej.nih.gov/ij/). The mean 
fluorescence intensity was measured from three regions: inside the targeted FRAP region, a 
reference region from a non-bleached stress granule, and a reference region from outside the cell. 
Image series where stress granules moved partly or completely away from the measurement or 
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bleaching regions, or where the bleaching caused an obvious intensity drop in the non-targeted 
stress granule were discarded. In total, 30 granules were analyzed of GFP-TIA1a p.E384K 
transfected cells, 27 of wild-type transfected cells and 36 of p.N357S transfected cells. 
 
The returned value for imaging background was subtracted from the measured fluorescence 
intensity value of the region of interest. This was done for each frame separately. The values for 
each analyzed granule were normalized to the initial fluorescence intensity (frame 1) of the series to 
make the values comparable. The values for all wild-type, p.E384K and p.N357S samples were then 
plotted together, and averaged to build a visualization of the data. 
 
Significance values were calculated in SPSS using the 2-tailed Mann-Whitney U test. 
 
8.9. COLD	  SHOCK	  (II)	  
Cold shock was induced 18h after transfection by transferring plates seeded with both GFP-TIA1a 
wild type and p.E384K (cultured in CO2-independend media by Invitrogen/Life Technologies) to 
the cold room at 9.0 –12.5°C for 4–8 h. The plates were placed directly on lead blocks pre-cooled to 
the cold room temperature and covered as to minimize temperature fluctuation and changes in 
lighting during the cold shock. The temperature was monitored during the cold shock treatment 
both inside and outside the insulation. 
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9. RESULTS	  AND	  DISCUSSION	  
9.1. SUBPROJECT	  I:	  SNP	  p.N357S	  
9.1.1.	  	  EXPRESSION	  AND	  SOLUBILITY	  TESTS	  
The intensity of the GFP-tagged bands in the blots (shown in green) for HeLa samples (Fig. 11) and 
293T samples (Fig. 12) was measured, normalized to the mean value of tubulin (shown in red on 
the blots) and compared against each other. No significant difference between the constructs was 
recorded.  
 
As seen from the HeLa blot (Fig. 11) the construct is transfectable and the HeLa cells can express 
the GFP-tagged TIA1 protein, as it is clearly visible in the blot. Furthermore, as expected, protein 
over-expression in 293T cells is significantly more effective than in HeLa cells, which is clearly 
seen when comparing the western blots in Fig. 12 to those in Fig. 11. 
 
 
Figure	   11.	   Expression	   and	   solubility	   test	   of	   TIA1	   isoforms	   a	   and	   b	   wild-­‐type,	   p.E384K	   and	   p.N357S	   in	   HeLa	   cells,	  
showing	   supernatant	   on	   the	   left	   and	   pellets	   on	   the	   right.	   The	   first	   sample	   of	   GFP-­‐TIA1b	   p.N357S	   and	   the	   second	  
sample	  of	  GFP-­‐TIA1a	  wt	  were	  excluded	  from	  the	  analysis	  due	  to	  pipetting	  errors.	  Tubulin	  shown	  in	  red,	  GFP	  in	  green.	  
 
 
Figure	  12.	  Expression	  and	  solubility	  test	  of	  TIA1	  isoforms	  a	  and	  b	  wild-­‐type,	  p.E384K	  and	  p.N357S	  in	  293T	  cells.	  Sample	  
GFP-­‐TIA1b	  wt	   in	   the	   left	  picture	  and	   the	   third	   supernatant	   sample	  of	  GFP-­‐TIA1b	  p.E384K,	  along	  with	  wells	   showing	  
overflow	  material	  were	  excluded	  from	  the	  analysis	  due	  to	  pipetting	  errors.	  Tubulin	  shown	  in	  red,	  GFP	  in	  green.	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As seen in Fig. 11 and 12, the expression and solubility tests returned similar results for the tests on 
both used cell lines, indicating no obvious difference between the samples within the sets. Based on 
this, the assumption was made that the amino acid change from asparagine to serine does not cause 
a significant change in TIA1 solubility. However, a functional difference in protein mechanisms 
cannot be ruled out by the confirmation of similar expression and solubility levels. 
 
9.1.2. CELLINSIGHT	  HIGH	  CONTENT	  IMAGE	  ANALYSIS	  (I) 	  
Fig. 13 shows an example of the images taken with the CellInsight platform. The used Hoechst-dye 
is targeted solely to the nuclei, as Hoechst targets DNA. The GFP-tagged TIA1 is shown in both the 
nuclei and the stress granules, which are seen as clear spots in the cytosol, often in close proximity 
to the nucleus. It is to be noted that the TIA1 in the cytosol is seen as distinct aggregates. The 
nucleus, however, shows a relatively even GFP-signal, indicating that TIA1 in the nucleus is not 
aggregated. 
 
 
Figure	  13.	  Image	  of	  the	  CellInsight	  analysis	  of	  untreated	  and	  sodium	  arsenite	  treated	  GFP-­‐TIA1a	  and	  b	  wt	  and	  p.N357S	  
cells.	  All	   nuclei	   are	  dyed	  with	  Hoechst.	   The	  GFP-­‐tagged	  TIA1	   is	   seen	   localized	   to	   the	  nuclei	   as	  well	   as	   to	   the	   stress	  
granules	   in	   the	   cytosol.	  Untransfected	   cells	   are	  not	   seen	   in	   the	  GFP-­‐images,	   because	   they	  do	  not	  express	   the	  GFP-­‐
tagged	  TIA1	  protein.	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It has been shown, that the p.E384K change in TIA1 causes a larger amount of stress granules to 
accumulate in the cytosol as compared to wild-type TIA1 both in untreated and arsenite treated cells 
(Hackman et al. 2013). It was hence expected, that the p.N357S change would cause a similar 
change in behavior of the protein. 
 
Unfortunately a portion of the data for the untreated TIA1a p.N357S didn’t meet quality standards 
and had to be excluded. The excluded cases were confirmed by manually investigating the primary 
imaging data and confirming bad quality of images or signal. Thus, the sample size was reduced, 
and there was additionally a large variance in the data values. No significant difference could thus 
be measured between the untreated TIA1a wild-type and p.N357S (shown in Fig. 14).  
 
In contrast to the untreated samples, a difference in stress granule number per cell was recorded in 
the arsenite treated samples. A number of wells had to be omitted from the analysis due to bad 
quality and lack of signal (confirmed as earlier). The significance of the difference was calculated 
by the 2-tailed Mann-Whitney U test, which returned a p value of 0.05 (shown in Fig. 14). 
 
Figure	  14.	  CellInsight	  spot	  count	  data.	  Each	  column	  represents	  the	  relative	  amount	  of	  stress	  granules	  per	  analyzed	  cell	  
as	   compared	   to	   the	   wild-­‐type	   untreated	   cells	   on	   the	   respective	   plate.	   The	   error	   bars	   represent	   the	   normalized	  
standard	  deviation	  of	   the	  well	  averages.	  Data	  was	  assembled	  from	  4	  plates,	  altogether	  12	  wells	   for	  TIA1a	  wild-­‐type	  
untreated,	   6	  wells	   for	   TIA1a	  p.N357S	  untreated,	   8	  wells	   for	   TIA1a	  wild-­‐type	   arsenite	   treated	   and	   7	  wells	   for	   TIA1a	  
p.N357S	   arsenite	   treated.	   The	   significance	   level	   of	   the	   difference	   of	   the	   arsenite	   treated	   samples	   is	   p	   =	   0.05.	   The	  
significance	  level	  was	  calculated	  according	  to	  the	  2-­‐tailed	  Mann-­‐Whitney	  U	  test. 
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No significant difference was recorded in spot area measurements and analyzes, which were 
performed in the same way as the quantification analysis above.  The spot size seems to vary a lot in 
between the groups, indicating that the mutation might not affect the mean stress granule size. 
 
Unfortunately transfections performed with the b isoform of the TIA1b p.N357S construct were 
systematically unsuccessful, and no data can be presented for the construct. Issues concerning the 
construct are discussed in the section 10.2. Subproject I specific errors. 
 
9.1.3. FLUORESCENCE	  RECOVERY	  AFTER	  PHOTOBLEACHING	  
The FRAP analysis was performed only using isoform a of TIA1 wild-type, p.E384K and p.N357S 
transfected HeLa cells, as there has been no recorded difference in performance between the 
isoforms a and b in either the wild-type or the p.E384K mutant, and no difference in performance 
had been recorded between the isoforms in the p.N357S either. 
 
It has earlier been shown, that the TIA1a p.E384K recovers significantly slower than the TIA1a 
wild-type after photobleaching. The aim was to recreate the p.E384K experiment and include 
p.N357S as well to distinguish possible functional differences between these two. The hypothesis 
was, that the p.N357S mutation would cause a similar decrease in the ability to recover as the 
p.E384K, as the mutation is in the same domain and could therefore behave similarly. 
 
It seems though, that the p.N357S mutation actually enables the stress granules to recover faster 
(shown in Fig. 15), possibly indicating that the mutation causes the protein to aggregate more easily 
than either the wild-type or the p.E384K mutated protein. 
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Figure	   15.	   Recovery	   of	   relative	   fluorescence	   intensity	   of	   stress	   granules	   after	   photobleaching	   in	   TIA1a	   wild-­‐type,	  
p.E384K	   and	   p.N357S	   transfected	   HeLa	   cells.	   The	   values	   are	   normalized	   to	   the	   initial	   intensity	   of	   the	   measured	  
stressgranules.	  The	  bleach	  was	  induced	  after	  frame	  5.	  The	  frames	  were	  taken	  at	  250	  ms	  intervals.	  The	  three	  sample	  
sets	  are	  offset	  by	  0.2	  arbitrary	  units	  on	  the	  x-­‐axis	  to	  avoid	  overlap	  of	  the	  representative	  figures.	  Significant	  differences	  
(p	  <	  0.05)	  between	  TIA1a	  p.E384K	  and	  p.N357S	  transfected	  cells	  are	  marked	  with	  and	  asterisk	  (*).	  P	  value	  calculated	  
according	  to	  the	  2-­‐tailed	  Mann-­‐Whitney	  U	  test.	  
 
 
Significant levels of difference could not be retrieved for the difference between the recovery of 
TIA1a wild-type and p.E384K stress granules, which has earlier been done (Hackman et al. 2013). 
Also the difference between TIA1a wild-type and p.N357S stress granules turned out to not be 
significant.  
 
However, a significant difference in recovery speed between TIA1a p.E384K and p.N357S was 
recorded. This would indicate, that the p.N357S change causes a different behavior to that of the 
Welander causing p.E384K change. The question remains whether the p.N357S behaves differently 
as compared to the wild-type. 
 
Although the results did not return significant values in statistical tests, the trend shown by figure 
15 could indicate, that the p.N357S change actually causes the protein to recover faster than the 
wild-type. As the change is in fact located in the PRD domain, which brings the protein its 
aggregation feature, it is plausible that any change in the domain in question would cause the 
protein to behave differently in aggregative situations. 
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9.2. SUBPROJECT	  II:	  THE	  EFFECT	  OF	  COLD	  SHOCK	  ON	  STRESS	  GRANULES	  
The effect of cold shock on stress granules has previously been investigated by Hofmann et al. 
(2012), who concluded that stress granules form at between 4 to 10 h in several different 
mammalian cell lines, when they are kept at 10°C. The idea was to recreate the experiment using 
GFP-tagged TIA1 as a stress granule marker to look at whether any significant differences are 
prevalent between wild-type and p.E384K transfected cells. An untreated and arsenite treated 
control was included in the experiment. 
 
What could directly be concluded from the results was, that the cells did not react well to the cold 
shock. Stress granule levels in untreated control cells were significantly higher than in cold shock 
treated cells (shown in Fig. 16). This is due to transfected HeLa cells over-expressing protein, and 
TIA1’s ability to create stress granules when over-expressed.  
 
Cold shock treated cells, on the other hand, go into a hibernation-like state, where their whole 
machinery is slowed down, the translation of protein and thus the rapid formation of stress granules 
included. One would think that keeping the cells in colder temperatures for a longer period of time 
would give them enough time to create stress granules regardless of the temperature, but 
unfortunately HeLa cells didn’t seem to take the cold too well, and longer treatment times were 
performed at the cost of cell viability. 
 
What is interesting in the results is the observable trend that each series follows the same pattern. 
Wild-types show smaller amounts of stress granules per cell than their respective p.E384K variants 
in untreated, arsenite treated and cold shock treated sets. Cold shocked cells showed somewhere 
between 60 and 75% of stress granules of their untreated controls, and the arsenite treated cells 
showed systematically more stress granules than either the untreated controls and the cold shock 
cells. 
 
There was no observed difference between the two isoforms in either the wild-type or the p.E384K 
samples. No difference has been recorded earlier either. 
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Figure	  16.	  CellInsight	  spot	  count	  data.	  Each	  column	  represents	  the	  relative	  amount	  of	  stress	  granules	  per	  analyzed	  cell	  
as	   compared	   to	   the	   wild-­‐type	   untreated	   cells	   on	   the	   respective	   plate.	   The	   error	   bars	   represent	   the	   normalized	  
standard	  deviation	  of	  the	  well	  averages.	  Data	  was	  assembled	  from	  2	  plates,	  altogether	  3	  wells	  for	  each	  sample.	  The	  
significance	  level	  (p	  value)	  of	  the	  difference	  between	  all	  untreated,	  arsenite	  treated	  and	  cold	  shock	  treated	  samples	  in	  
each	   group	   is	   <0.05,	   except	   for	   the	   difference	   between	   the	   untreated	   and	   arsenite	   treated	   TIA1a	   wild-­‐type.	   The	  
significance	   level	  between	  the	  cold	  shocked	  TIA1a	  wild-­‐type	  and	  p.E384K	  was	  0.051.	  The	  significance	   level	  between	  
the	   cold	   shocked	   TIA1b	   wild-­‐type	   and	   p.E384K	   was	   0.108.	   The	   significance	   level	   was	   calculated	   according	   to	   an	  
independent	  sample	  T-­‐test.	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10. EVALUATION	  OF	  SOURCES	  OF	  ERROR	  
The variance in data observed between different experiments is partially explained by lack of 
routine and thus inconsistency in the methods. This could have been corrected by increasing 
attentiveness in the work and increasing care in general, although everything was performed with 
the most care possible at the time being. Adopting a consistent routine would also lead to all steps 
being performed at a higher and more regular pace, leading less differences between different 
sample sets. 
 
The whole process of creating, imaging and analyzing data for the CellInsight platform is rather 
long and scattered with possible bottlenecks. The cells have to be transfected, stressed and fixed, 
imaged and then analyzed. If an error is made at one of these points, the resulting data will be 
compromised or return null results – for example, if the CellInsight instrument images pictures of 
low quality due to an unsuccessful transfection or fixation of the cells, the SpotCount software will 
not be able to return valid data for the well or plate in question. 
 
In addition to problems related to sample treatment, tilts, bends, and scratches of the plate lead to 
imaging problems. The CellInsight apparatus is unable to focus properly if the plate is somehow 
damaged. These damages can appear during laboratory work, but also during manufacturing and 
shipping, and are virtually impossible to observe by the naked eye.  
 
In practice, there was sometimes problems with transfection, which probably were caused by loss of 
attentiveness during work, pipetting errors and other mundane sources of error, that eventually 
resulted in loss of (analyzable) data. However, this is probably a minor factor. 
 
Also, when plating cells on a 24-well plate, it should be noted that they easily accumulate on the 
edges of the well, if plated with too much force or velocity. If the cells are accumulated at the 
borders of the well, it causes problems at the imaging, as the CellInsight platform’s focus capacity 
is best in the middle of a well and it is thus preferable to image the center, rather than the edges of 
the well. Therefore, if the cells are attached in the outskirts of the well and the middle is rather 
scarcely plated, the amount and quality of the acquired data might be reduced. 
 
Part of the data had to be omitted from the analysis due to different reasons (such as the 
aforementioned issues), causing the results to be based on less data than what would be optimal.  
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The only way to correct this would be to repeat the experiments, and paying close attention to the 
now known tricky phases of the protocols. Assuming that the samples have been successfully 
produced, fixed plates could be imaged again and already existing images could be reanalyzed by 
running them through the software with an optimized protocol.  
 
10.1. SUBPROJECT	  I	  SPECIFIC	  ERRORS	  
Transfection issues were more prominent in subproject I than in subproject II. Of the two created 
constructs, the isoform b did not transfect properly into the cells and data for that isoform was thus 
lacking. As the error seems to systemically appear for all isoform b p.N357S transfected cells even 
on the same plates where the isoform a is transfected as expected, it seems more plausible that there 
is an error in the pEGFP-TIA1b p.N357S plasmid itself, rather than in the methods used.  
 
The plasmid sequence was analyzed and confirmed by sequencing only for the insert and the 
flanking sequences of the plasmid. There might thus be unnoticed errors in the plasmid sequence. 
The transfection problems may also be caused by a contamination in the plasmid sample. However, 
there should be no reason to believe that these would be the primary reasons for the transfection 
difficulties and problems with the isoform b.  
 
The FRAP analysis was performed within 55 minutes after the arsenite treatment. It is known, that 
stress granules start to dissolve within minutes of stress relief, but seen that the stress granule 
number in the transfected cells analyzed did not seem to significantly decrease within this time 
frame, this does not appear to be an issue in these experiments.  
 
In addition, each analyzed stress granule’s frames are taken at slightly different time points due to 
the instrument’s features, resulting in that the same frame number for two different analyzed cells 
might not be taken at the exact same millisecond after bleaching. The process of normalizing the 
time points was, however, not performed. In stead it was assumed, that the time difference was 
negligible, and that the intensity levels for each frame were comparable with one another. This may 
or may not affect the FRAP results. The sample order was changed between different analysis 
times, so this should, however, not be an issue. 
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10.2. SUBPROJECT	  II	  SPECIFIC	  ERRORS	  
There were several problems faced throughout the cold shock experiment, and it called for a lot of 
problem solving and application of inventive solutions, unfortunately resulting in rather inconsistent 
results. The protocol used was based on the Hofmann et al. 2012 paper, but there were several 
differences to the Hofmann experiment, among others the lack of similar premises. 
 
Ideally, the untreated control would be included on the same 24-well-plate as the cold shock treated 
cells. This could not be executed, as there are no means of thermally insulating the plate in half. The 
only option would have been to only seed cells in the outermost wells and create thermal insulates 
for the two halves. This would have significantly reduced the sample size per plate and been 
difficult to implement in practice. Thus, I opted for accuracy in seeding and handling of the cold 
shock and control cells and kept them on separate plates. 
 
The cold shock was performed paying attention and recording possible factors affecting the 
temperature, such as draft. The lead blocks on which the plates were placed were pre-chilled to the 
ambient temperature, which should be stable enough. However, the effect of draft caused by 
opening the door of the cold room and warm air flowing in to the room cannot be completely 
neglected, and could not be controlled either. Ideally, the cold shock would be performed in a 
completely insulated space with possibility to accurately regulate the temperature, such as a cooling 
centrifuge or optimally a cooling incubator. 
 
The big variability in the cold shock CellInsight results is a direct cause of the inconsistent 
experiment conditions. The results were also compromised by the HeLa cells, which did not react 
well to the treatment, and were thus omitted in the SpotCount analysis by the software due to 
abnormal cell and nuclei shape. A significant level of cell death due to cold shock was also 
observed, obviously compromising the results. 
 
The Hofmann paper (Hofmann et al. 2012) used significantly longer treatment times for the cells 
(10 h), but it is also to be noted that their experiment used untransfected COS7 cells and their 
confirmed hypothesis was that cold-shock induces stress granules formation. The mention of stress 
granule formation in HeLa cells is very brief and only performed as a control in their article.  
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It could be considered to do the cold shock in lower temperatures and reducing the exposure time 
significantly, thus not having to expose the cells to mild cold temperatures during longer times, 
which they do not seem to take well, as the imaging of the plates revealed an abnormal amount of 
dead cells. However, if the temperature is lowered too much, the cells risk to slow down their 
machinery so much, that they would outright stop all their metabolic activity in stead of the 
treatment inducing a stress response. Another option would be to increase the temperature to 
somewhere between 37 °C and the used 9-12 °C and significantly increase the treatment time as to 
see if the treatment would work as intended. 
 
Due to the different behavior of p.N357S and p.E384K in stress granule dynamics, it would be of 
interest to repeat the cold shock test with a larger set of data with both constructs and considering 
alternative methods to the conduct of the test. A better way to stabilize the temperature and a more 
consistent exposure to the cold shock could be considered. 
 
In addition, it could be considered to change cell line for the cold shock experiment. Hofmann et al. 
successfully used COS7 cells in their experiment. Experimenting whether the loss of viability in 
HeLa cells is caused by the transfection or the cold shock should be established, alongside with 
whether COS7 tolerate the treatment when transfected and over-expressing as well. 
 51 
11. CONCLUSIONS	  AND	  FUTURE	  PROSPECTS	  
The findings of this project do suggest that the p.N357S change in TIA1 has an effect on the 
protein, changing its functional properties. The results indicate that the mutation may lead to the 
protein being more prone to aggregate with itself, thus creating stress granules that may assemble 
faster than the wild type (unconfirmed) and the Welander-causing p.E384K change protein 
(confirmed). 
 
Since the mutation is located in the PRD domain, which is in charge of the protein’s aggregation 
feature, the belief that the p.N357S change would have an impact on the aggregative attributes of 
the translated protein are not far fetched.  
 
Within the PRD domain, the Welander causing p.E384K change changes the amino acid residue of 
glutamic acid to a lysine by a single base pair change. Glutamic acid is a negatively charged amino 
acid harboring a carboxyl group in its chain, and also acidic, as indicated in its name. Lysine, on the 
other hand, is positively charged due to its amino group in its chain and has basic features. There is 
thus a significant difference in the attributes of these two amino acids, which seems to correlate 
with the functionality of the protein. 
 
In the case of the p.N357S mutation, an asparagine is exchanged for a serine in the amino acid 
sequence of the protein. Both amino acids belong to the group of amino acids with side chains that 
are uncharged, yet polar. Serine harbors a hydroxyl group at its free end, while asparagine harbors 
an amide group.  
 
The experiments with TIA1 harboring the p.N357S change have not been conducted earlier, and it 
is not known whether similar experiments have been performed elsewhere during this thesis 
process. The results acquired are thus, as far as known, new to science.  
 
It is not known, whether cold shock experiments with HeLa cells over-expressing any stress granule 
containing proteins have been conducted earlier or during this thesis process. The results indicate, 
that the process may be hard and that the cold shock protocol calls for optimization in order to yield 
trustful results. Although the results were narrow, it was shown that HeLa cells do indeed form 
stress granules under cold-shock, and a trend for p.E384K cells to accumulate more granules than 
the wild-type expressing cells was also noticed, although not significant. 
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Due to the different behavior of p.N357S and p.E384K, it would be of interest to repeat the cold 
shock test with a larger set of data with both constructs and considering alternative methods to the 
conduct of the test, along with an optimization of the protocol. A better way to stabilize the 
temperature and a more consistent exposure to the cold shock should be considered. 
 
As it is known that the p.E384K mutation in TIA1 is responsible for causing Welander Distal 
Myopathy, the idea of the p.N357S change to be pathogenic is therefore not too far fetched. During 
the time of this project, other studies done at Folkhälsan Research Center found even more of the 
p.N357S change in patients with a Welander-like phenotype. However, the mutation appears to 
occur in connection with other mutations, leading to the belief that it might be involved in a 
myopathy with a polygenic background (personal communication). Distal myopathies have long 
been considered diseases of monogenic background, and this finding might revolutionize the field. 
 
Thus, the research will continue and tests are to be made using the p.N357S construct in connection 
with the other genetic mutations in order to reveal whether these changes are pathogenic. 
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SUPPLEMENTS	  
SUPPLEMENT	  1:	  The	  pEGFP	  plasmid	  map	  
 
 
 
 
The TIA1a insert is located between the BamHI and HindIII sites in the multiple cloning site of the 
pEGFP plasmid. Plasmid map from AddGene (https://www.addgene.org/vector-database/2491/).  
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SUPPLEMENT	  2:	  Mutagenic	  PCR	  conditions	  
 
Forward primer:  5’-[phos]CACCATGGATGGGACCAA-3’ 
Reverse primer:  5’-[phos]AGGCGGTTGCACTCCATAAC-3’ 
 
 
Tm calculator: 
https://www.lifetechnologies.com/fi/en/home/brands/thermo-scientific/molecular-
biology/molecular-biology-learning-center/molecular-biology-resource-library/thermo-scientific-
web-tools/tm-calculator.html 
 
 
 
Table	  A. Mutagenic PCR reaction mix for pEGFP-TIA1 p.N357S point mutation induction using Phusion polymerase. 
Reagent	   Amount/reaction	   Specification	  
Water 12.4 µl MilliQ 
Phusion buffer (5x) 4.0 µl Phusion High-Fidelity buffer 
10 mM dNTPs 0.4 µl dATP, dCTP, dGTP, dTTP, 2.5 mM each 
10 µM forward primer 1.0 µl  
10 µM reverse primer 1.0 µl  
Template DNA (10 ng/µl) 1.0 µl  
Enzyme 0.2 µl Phusion High-Fidelity DNA Polymerase 
Σ 20 µl  
 
 
 
 
Table	  B. Mutagenic PCR program for pEGFP-TIA1 p.N357S point mutation induction using Phusion polymerase. 
 Phase	   Temperature	   Time	  
1	   Initial denaturation 98ºC 30 s 
2	   Denaturation 98ºC 10 s 
3	   Melting 66ºC 30 s 
4	   Annealing 72ºC 180 s 
5	   Final extension 72ºC 10 min 
6	   Hold 6ºC Hold 
Steps 2-4 repeated 30 times, total time approximately 2 h 15 min. 
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SUPPLEMENT	  3:	  TIA1a	  and	  b,	  wt,	  p.E384K	  and	  p.N357S	  amino	  acid	  sequence	  
 
Legend: 
Amino acid sequence 
11 aa sequence unique to isoform a, excluded in b 
Isoform dependent variation [a/b] 
p.N357S variation [wild-type/mutant] 
p.E384K variation [wild-type/mutant] 
 
MEDEMPKTLYVGNLSRDVTEALILQLFSQIGPCKNCKMIMDTAGNDPYCFVEFHEHRHAAAALAAM
NGRKIMGKEVKVNWATTPSSQKKDTSSSTVVSTQRSQ[D/N]HFHVFVGDLSPEITTEDIKAAFAP
FGRISDARVVKDMATGKSKGYGFVSFFNKWDAENAIQQMGGQWLGGRQIRTNWATRKPPAPKSTYE
SNTKQLSYDEVVNQSSPSNCTVYCGGVTSGLTEQLMRQTFSPFGQIMEIRVFPDKGYSFVRFNSHE
SAAHAIVSVNGTTIEGHVVKCYWGKETLDMINPVQQQNQIGYPQPYGQWGQWYGNAQQIGQYMPNG
WQVPAYGMYGQAWNQQGFNQTQSSAPWMGP[N/S]YGVQPPQGQNGSMLPNQPSGYRVAGY[E/K]
TQ 
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SUPPLEMENT	  4:	  pEGFP-­‐TIA1a	  and	  b,	  wt,	  p.E384K	  and	  p.N357S	  DNA	  
sequence	  
	  
Legend: 
EGFP plasmid sequence 
TIA1 sequence 
33 bp sequence unique to isoform a, excluded in b 
p.N357S variation [wild-type/mutant] 
p.E384K variation |wild-type/mutant] 
 
 
TAGTTATTAATAGTAATCAATTACGGGGTCATTAGTTCATAGCCCATATATGGAGTTCCGCGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCG
CCCAACGACCCCCGCCCATTGACGTCAATAATGACGTATGTTCCCATAGTAACGCCAATAGGGACTTTCCATTGACGTCAATGGGTGGAGTATTTACGGT
AAACTGCCCACTTGGCAGTACATCAAGTGTATCATATGCCAAGTACGCCCCCTATTGACGTCAATGACGGTAAATGGCCCGCCTGGCATTATGCCCAGTA
CATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTACGTATTAGTCATCGCTATTACCATGGTGATGCGGTTTTGGCAGTACATCAATGGGCGTGGA
TAGCGGTTTGACTCACGGGGATTTCCAAGTCTCCACCCCATTGACGTCAATGGGAGTTTGTTTTGGCACCAAAATCAACGGGACTTTCCAAAATGTCGTA
ACAACTCCGCCCCATTGACGCAAATGGGCGGTAGGCGTGTACGGTGGGAGGTCTATATAAGCAGAGCTGGTTTAGTGAACCGTCAGATCCGCTAGCGCTA
CCGGTCGCCACCATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCG
TGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGAC
CACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAG
CGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCG
ACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAA
GGTGAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTACCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTG
CCCGACAACCACTACCTGAGCACCCAGTCCGCCCTGAGCAAAGACCCCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGA
TCACTCTCGGCATGGACGAGCTGTACAAGTCCGGACTCAGATCTCGAGCTCAAGCTTCGAATTCTGCAGTCGACGAGGACGAGATGCCCAAGACTCTATA
CGTCGGTAACCTTTCCAGAGATGTGACAGAAGCTCTAATTCTGCAACTCTTTAGCCAGATTGGACCTTGTAAAAACTGCAAAATGATTATGGATACAGCT
GGAAATGATCCCTATTGTTTTGTGGAGTTTCATGAGCATCGTCATGCAGCTGCAGCATTAGCTGCTATGAATGGACGGAAGATAATGGGTAAGGAAGTCA
AAGTGAATTGGGCAACAACCCCTAGCAGTCAAAAGAAAGATACAAGCAGTAGTACCGTTGTCAGCACACAGCGTTCACAAGATCATTTCCATGTCTTTGT
TGGTGATCTCAGCCCAGAAATTACAACTGAAGATATAAAAGCTGCTTTTGCACCATTTGGAAGAATATCAGATGCCCGAGTGGTAAAAGACATGGCAACA
GGAAAGTCTAAGGGATATGGCTTTGTCTCCTTTTTCAACAAATGGGATGCTGAAAACGCCATTCAACAGATGGGTGGCCAGTGGCTTGGTGGAAGACAAA
TCAGAACTAACTGGGCAACCCGAAAGCCTCCCGCTCCAAAGAGTACATATGAGTCAAATACCAAACAGCTATCATATGATGAGGTTGTAAATCAGTCTAG
TCCAAGCAACTGTACTGTATACTGTGGAGGTGTTACTTCTGGGCTAACAGAACAACTAATGCGTCAGACTTTTTCACCATTTGGACAAATAATGGAAATT
CGAGTCTTTCCAGATAAAGGATATTCATTTGTTCGGTTCAATTCCCATGAAAGTGCAGCACATGCAATTGTTTCTGTTAATGGTACTACCATTGAAGGTC
ATGTTGTGAAATGCTATTGGGGCAAAGAAACTCTTGATATGATAAATCCCGTGCAACAGCAGAATCAAATTGGATATCCCCAACCTTATGGCCAGTGGGG
CCAGTGGTATGGAAATGCACAACAAATTGGCCAGTATATGCCTAATGGTTGGCAAGTTCCTGCATATGGAATGTATGGCCAGGCATGGAACCAGCAAGGA
TTTAATCAGACACAGTCTTCTGCACCATGGATGGGACCAA[A/G]TTATGGAGTGCAACCGCCTCAAGGGCAAAATGGCAGCATGTTGCCCAATCAGCCT
TCTGGGTATCGAGTGGCAGGGTAT[G/A]AAACCCAGTGAAAGGGCGAATTCCAGCACACTGGCGGCCGTTACTAGTGGATCCAAACGGATCTAGATAAC
TGATCATAATCAGCCATACCACATTTGTAGAGGTTTTACTTGCTTTAAAAAACCTCCCACACCTCCCCCTGAACCTGAAACATAAAATGAATGCAATTGT
TGTTGTTAACTTGTTTATTGCAGCTTATAATGGTTACAAATAAAGCAATAGCATCACAAATTTCACAAATAAAGCATTTTTTTCACTGCATTCTAGTTGT
GGTTTGTCCAAACTCATCAATGTATCTTAACGCGTAAATTGTAAGCGTTAATATTTTGTTAAAATTCGCGTTAAATTTTTGTTAAATCAGCTCATTTTTT
AACCAATAGGCCGAAATCGGCAAAATCCCTTATAAATCAAAAGAATAGACCGAGATAGGGTTGAGTGTTGTTCCAGTTTGGAACAAGAGTCCACTATTAA
AGAACGTGGACTCCAACGTCAAAGGGCGAAAAACCGTCTATCAGGGCGATGGCCCACTACGTGAACCATCACCCTAATCAAGTTTTTTGGGGTCGAGGTG
CCGTAAAGCACTAAATCGGAACCCTAAAGGGAGCCCCCGATTTAGAGCTTGACGGGGAAAGCCGGCGAACGTGGCGAGAAAGGAAGGGAAGAAAGCGAAA
GGAGCGGGCGCTAGGGCGCTGGCAAGTGTAGCGGTCACGCTGCGCGTAACCACCACACCCGCCGCGCTTAATGCGCCGCTACAGGGCGCGTCAGGTGGCA
CTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAAATACATTCAAATATGTATCCGCTCATGAGACAATAACCCTGATAAATGCTTCA
ATAATATTGAAAAAGGAAGAGTCCTGAGGCGGAAAGAACCAGCTGTGGAATGTGTGTCAGTTAGGGTGTGGAAAGTCCCCAGGCTCCCCAGCAGGCAGAA
GTATGCAAAGCATGCATCTCAATTAGTCAGCAACCAGGTGTGGAAAGTCCCCAGGCTCCCCAGCAGGCAGAAGTATGCAAAGCATGCATCTCAATTAGTC
AGCAACCATAGTCCCGCCCCTAACTCCGCCCATCCCGCCCCTAACTCCGCCCAGTTCCGCCCATTCTCCGCCCCATGGCTGACTAATTTTTTTTATTTAT
GCAGAGGCCGAGGCCGCCTCGGCCTCTGAGCTATTCCAGAAGTAGTGAGGAGGCTTTTTTGGAGGCCTAGGCTTTTGCAAAGATCGATCAAGAGACAGGA
TGAGGATCGTTTCGCATGATTGAACAAGATGGATTGCACGCAGGTTCTCCGGCCGCTTGGGTGGAGAGGCTATTCGGCTATGACTGGGCACAACAGACAA
TCGGCTGCTCTGATGCCGCCGTGTTCCGGCTGTCAGCGCAGGGGCGCCCGGTTCTTTTTGTCAAGACCGACCTGTCCGGTGCCCTGAATGAACTGCAAGA
CGAGGCAGCGCGGCTATCGTGGCTGGCCACGACGGGCGTTCCTTGCGCAGCTGTGCTCGACGTTGTCACTGAAGCGGGAAGGGACTGGCTGCTATTGGGC
GAAGTGCCGGGGCAGGATCTCCTGTCATCTCACCTTGCTCCTGCCGAGAAAGTATCCATCATGGCTGATGCAATGCGGCGGCTGCATACGCTTGATCCGG
CTACCTGCCCATTCGACCACCAAGCGAAACATCGCATCGAGCGAGCACGTACTCGGATGGAAGCCGGTCTTGTCGATCAGGATGATCTGGACGAAGAGCA
TCAGGGGCTCGCGCCAGCCGAACTGTTCGCCAGGCTCAAGGCGAGCATGCCCGACGGCGAGGATCTCGTCGTGACCCATGGCGATGCCTGCTTGCCGAAT
ATCATGGTGGAAAATGGCCGCTTTTCTGGATTCATCGACTGTGGCCGGCTGGGTGTGGCGGACCGCTATCAGGACATAGCGTTGGCTACCCGTGATATTG
CTGAAGAGCTTGGCGGCGAATGGGCTGACCGCTTCCTCGTGCTTTACGGTATCGCCGCTCCCGATTCGCAGCGCATCGCCTTCTATCGCCTTCTTGACGA
GTTCTTCTGAGCGGGACTCTGGGGTTCGAAATGACCGACCAAGCGACGCCCAACCTGCCATCACGAGATTTCGATTCCACCGCCGCCTTCTATGAAAGGT
TGGGCTTCGGAATCGTTTTCCGGGACGCCGGCTGGATGATCCTCCAGCGCGGGGATCTCATGCTGGAGTTCTTCGCCCACCCTAGGGGGAGGCTAACTGA
AACACGGAAGGAGACAATACCGGAAGGAACCCGCGCTATGACGGCAATAAAAAGACAGAATAAAACGCACGGTGTTGGGTCGTTTGTTCATAAACGCGGG
GTTCGGTCCCAGGGCTGGCACTCTGTCGATACCCCACCGAGACCCCATTGGGGCCAATACGCCCGCGTTTCTTCCTTTTCCCCACCCCACCCCCCAAGTT
CGGGTGAAGGCCCAGGGCTCGCAGCCAACGTCGGGGCGGCAGGCCCTGCCATAGCCTCAGGTTACTCATATATACTTTAGATTGATTTAAAACTTCATTT
TTAATTTAAAAGGATCTAGGTGAAGATCCTTTTTGATAATCTCATGACCAAAATCCCTTAACGTGAGTTTTCGTTCCACTGAGCGTCAGACCCCGTAGAA
AAGATCAAAGGATCTTCTTGAGATCCTTTTTTTCTGCGCGTAATCTGCTGCTTGCAAACAAAAAAACCACCGCTACCAGCGGTGGTTTGTTTGCCGGATC
AAGAGCTACCAACTCTTTTTCCGAAGGTAACTGGCTTCAGCAGAGCGCAGATACCAAATACTGTCCTTCTAGTGTAGCCGTAGTTAGGCCACCACTTCAA
GAACTCTGTAGCACCGCCTACATACCTCGCTCTGCTAATCCTGTTACCAGTGGCTGCTGCCAGTGGCGATAAGTCGTGTCTTACCGGGTTGGACTCAAGA
CGATAGTTACCGGATAAGGCGCAGCGGTCGGGCTGAACGGGGGGTTCGTGCACACAGCCCAGCTTGGAGCGAACGACCTACACCGAACTGAGATACCTAC
AGCGTGAGCTATGAGAAAGCGCCACGCTTCCCGAAGGGAGAAAGGCGGACAGGTATCCGGTAAGCGGCAGGGTCGGAACAGGAGAGCGCACGAGGGAGCT
TCCAGGGGGAAACGCCTGGTATCTTTATAGTCCTGTCGGGTTTCGCCACCTCTGACTTGAGCGTCGATTTTTGTGATGCTCGTCAGGGGGGCGGAGCCTA
TGGAAAAACGCCAGCAACGCGGCCTTTTTACGGTTCCTGGCCTTTTGCTGGCCTTTTGCTCACATGTTCTTTCCTGCGTTATCCCCTGATTCTGTGGATA
ACCGTATTACCGCCATGCAT 
 
